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Chapter 1 
GENERAL INTRODUCTION 

1 General Introduction 
Alopecia areata is after alopecia androgenetica the most frequent hair disease. 
Alopecia areata affects 2% of patients presenting to dermatological outpatient 
departments in Great Britain and the USA1. The term "alopecia" (άλωπίκία = fox 
disease) was first used by Hippocrates. The term "area" is known from Celsius. The 
term "alopecia areata" was introduced by de Sauvages2. 
After many years of research, it is still a disease of unknown etiology, though 
evidence for an autoimmune etiology continues to mount. 
1.1 CLINICAL ASPECTS 
Clinical manifestations and course 
The hallmark of alopecia areata is the well-circumscribed round or oval patch of 
nonscarring hair loss. Alopecia areata is characterized by hair loss, mostly on the 
scalp, although it may also be seen, firstly on the eyebrows, eyelashes, beard, 
genital area or other parts of the body. When the hair loss appears, mostly no 
additional symptoms are present, but some patients have the experiences, that the 
hair loss may be accompanied by itching, stinging, slight local pain or tension. In 
the strict sense the term alopecia areata is restricted to the patchy hair loss, mostly 
on the scalp. The term "alopecia areata" is also used as a general designation of the 
disease, irrespective of the type and the localisation on the body. Different types are 
there to be distinguished: the most frequent form is the isolated, asymptomatic, non-
scarring loss of the hair from a circumscribed plaque (patchy type) (Fig. 1), usually 
on the scalp. Hair loss may involve all of the scalp, i.e. alopecia totalis (Fig. 2), or 
the entire body, designated as alopecia universalis. In the ophiasis type, the hair loss 
is restricted to the occipital and temporal areas of the scalp (Fig. 3). In the diffuse 
type a scattered hair loss is found. The onset is usually sudden and the clinical 
course is exceedingly variable, with some cases resolving spontaneously and others 
progressing to loss of all scalp hair or all body hair. Recurrences are frequent even 
in patients who recover fully from their initial episode. 
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Fig. 1. Alopecia areata: patchy type 
Fig. 2. Alopecia areata totalis 
Fig. 3. Alopecia areata of the ophiasis type 
4 Chapter 1 
"Exclamation mark hairs" are a prominent diagnostic feature of active lesions of 
alopecia areata, and are often seen near the margin of spreading lesions. 
The distal part of such a hair shows normal thickness, but it tapers off towards its 
proximal part, indicating disturbed hair follicle keratinization shortly before the 
onset of alopecia becomes clinically apparent. Also the "points noirs" , the cadaveric 
hairs, as remnants of dystrophic hair roots in the follicle, found at the margins of 
alopecia areata lesions, are characteristic of an active alopecia areata. 
Simultaneously, reduced hair pigmentation, resulting in a sudden blanching (poliosis) 
has been reported4. Regrowing hairs in alopecia areata lesions are thin and often 
without pigment, mostly seen in the centre of the lesion, expanding in a ringlike 
pattern. 
Nail disorders (Fig. 4) occur in 10% of the patients3. Most distinctive and 
common is an extensive fine pitting of the surface of the nail plate, with a tendency 
toward geometric patterning ("sandpaper nails")3. Longitudinal ridging, thickening, 
brittleness, generalized opacity, onycholysis, onychomadesis, and red spotted lunula 
occur in patients developing alopecia areata or in patients with a progressive course. 
Lymphadenopathy, of the occipital and mastoidal lymph nodes, may occur in 
patients with more extensive involvement, i.e., in alopecia areata totalis and 
universalis and in the acute progressive course of the disease. 
Fig. 4. Nail changes in a patient with a severe alopecia areata: pits and longitudinal ridging 
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Epidemiology 
In the general population the risk for alopecia areata is 0.05-0.1%5. The onset of 
alopecia areata can be at any age. In 84% of the patients, the first clinical manifesta-
tion proved to appear before the age of 406. In a group of 736 patients less than 2% 
developed alopecia areata before the age of 2 years7. The reported sex incidences 
vary widely, in most countries both sexes are equally affected8. The course of the 
disease tends to be more severe when it has its onset before puberty. The familial 
incidence of alopecia areata varies between 10% and 25 %5. Regardless of the type 
of alopecia areata present in a parent, the estimated risk of children for the 
development of a severe type of alopecia areata is approximately 2%9. Although the 
clinical diagnosis is generally easy, sometimes a biopsy is necessary in order to 
differentiate alopecia areata from other hair disorders. 
Associated diseases 
The vast majority of patients with alopecia areata are in excellent health and do not 
have associated clinical conditions. There is a striking clinical association of alopecia 
areata and the atopic syndrome (10-26%)5. Alopecia areata occurs more often in 
Down's syndrome (9%)10. The following autoimmune disorders have been reported 
in association with alopecia areata: vitiligo, ulcerative colitis, intestinal polyposis, 
polyneuropathy, pernicious anaemia, Addison's disease, autoimmune testicular 
disease, various ocular changes, autoimmune atrophic gastritis, thyroid disease 
including Hashimoto's disease, various connective tissue diseases, myasthenia 
gravis, thymoma, agammaglobulinemia, hypogammaglobulinemia, autoimmune 
adrenal insufficiency, Candida endocrinopathy syndrome and polyglandular 
autoimmune syndrome. These associations are relatively weak and of no significance 
with respect to the individual patient. There is no indication for screening for these 
autoimmune diseases in patients with alopecia areata. 
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1.2 HISTOPATHOLOGIC AL ASPECTS 
Hair follicle 
The hair follicle which produces the hair fiber is divided into three parts": the lower 
portion, extending from the base of the follicle to the insertion of the arrector pili 
muscle; the middle portion or isthmus, a rather short section, extending from the 
insertion of the arrector pili muscle to the entrance of the sebaceous duct; and the 
upper portion or infundibulum, extending from the entrance of the sebaceous duct to 
the follicular orifice (Fig. 5). In the hair bulb (the deep bulbous end of each hair 
follicle), the hair matrix (a germinative layer of epithelial cells) provides new cells 
that differentiate into the cells of the hair and the surrounding inner root sheath. At 
the level of the hair bulb, the lower portion of the anagen hair follicle is composed 
of: the dermal papilla; the hair matrix; the hair, consisting inward to outward of 
medulla, cortex and hair cutícula; the inner root sheath, consisting inward to 
outward of the inner root sheath cuticle, Huxley layer and Henle layer; and the outer 
root sheath. The glassy or vitreous membrane separates the connective tissue sheath 
from the outer root sheath. The entire hair follicle is surrounded by a connective 
tissue sheath, which is continuous with the subepidermal connective tissue and 
protrudes into the hair bulb as the dermal papilla. 
Fig. 5. Schematic drawing of an anagen hair follicle 
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Hair growth cycle 
The formation of hair growth follows a cyclic pattern11. Each cycle comprises three 
phases: (1) an anagen (growth) phase; (2) a catagen (involution) phase and (3) a 
telogen (resting) phase. During anagen, the lower part of the hair follicle is fully 
developed, matrix cells are mitotically active and are the progenitors of the hair 
shaft and the inner root sheath, whereas the hair grows at a steady state. During 
catagen, melanin production and mitotitic activity has ceased by the matrix cells in 
the hair bulb. The hair stops growing. The epithelium of the lower part of the hair 
follicle involutes as a result from cell necrosis, resulting in a thin cord of epithelial 
cells surrounded by the collapsed, wrinkled, and thickened connective tissue sheath. 
The follicle regresses to about one-third its length, setting the dermal papilla free, 
and a club-hair begins to form, as a result of the surrounding of the lower end of the 
hair shaft by dense, trichilemmal keratin, which is formed by the outer root sheath. 
Finally, the telogen phase is reached. This stage is characterized by a total 
keratinization of the club-shaped lower end of the hair, localized at the level of the 
isthmus. During the late part of the telogen phase, the connection between the club-
shaped lower end of the hair and the follicular sac is loose. When regrowth begins, 
the cells in the bulge (point of insertion of the arrector pili muscle) begins to 
elongate by cell division and grows down as an epithelial column together with the 
dermal hair papilla inside of the old, collapsed fibrous root sheath of the previous 
hair. A new hair bulb is formed, representing the beginning of the new anagen 
phase. 
Alopecia areata 
The histolopathological picture of alopecia areata varies with the stage and the 
activity of the disease. The disorder is characterized by a cell-mediated process. A 
characteristic finding in alopecia areata is the presence of miniature hair structures. 
During the early stages of alopecia areata most of the hair follicles pass through the 
telogen phase. Hair loss is accompanied by a transition of hair follicles from the 
anagen to the telogen phase12. 
In the acute, progressive phase, a peribulbar inflammatory infiltrate sur-
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rounds the early anagen hair bulbs like a "swarm of bees", and there is also 
infiltration of the lymphocytes in the hair matrix epithelium. This peribulbar 
infiltrate consists predominantly of Τ lymphocytes with an increased T4/T8 ratio. 
The composition of this infiltrate changes in the different stages of the disease and 
during treatment1314. During the phase of acute hair loss there is a failure of matrix 
cells and matrical melanocytes resulting in the formation of dysplastic dyschromic 
hair shafts. 
In long-standing, chronic alopecia areata, the inflammatory changes are still 
observed. The number of anagen hair follicles is clearly reduced and the number of 
cells surrounding these follicles is rather low. The inflammatory cells often invade 
the matrix of the bulb and the outer root sheath of early anagen hairs". 
1.3 ETIOLOGY AND PATHOGENESIS 
Despite considerable clinical and basic scientific research, the etiology of alopecia 
areata remains so far unknown. However, research of the last years strongly 
suggests that immune mediated mechanisms may play a pivotal role in the 
pathogenesis of alopecia areata: 
(1) the statistical association of alopecia areata with diseases of 
autoimmune origin and disorders of a possible immunologic nature 
(2) the therapeutic response to agents known to modulate cell mediated 
mechanisms 
(3) abnormal high expression of class I major histocompatibility complex 
(MHC) antigens HLA-ABC in the hair matrix15, the expression of 
class II MHC HLA-DR antigens by follicular epithelium16 in long-
lasting alopecia areata and the expression of HLA-DQ" 
(4) in the early phase of the disease intrabulbar and peribulbar OKT 6-
positive cells (Langerhans cells) can be found18; these antigen-present­
ing cells play an important role in the initiation of the Τ cell mediated 
immune response 
(5) alterations in cell-mediated immunity are present, resulting in a 
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peribulbar infiltrate consisting predominantly of Τ lymphocytes12 and 
in an infiltration of the hair matrix by Τ cells19; measurements of the 
number of circulating Τ cells and the peripheral CD4/CD8 ratio did 
not yield consistent results, and do not appear to be a reliable parame­
ter for the disease activity 
(6) alterations of the humoral immunity resulting in the occurrence of 
various auto-antibodies, including anti-nuclear, anti-thyroid, anti-
parietal, anti-endothelial, anti-smooth muscle have been reported, 
however these antibodies were not a consistent finding in all alopecia 
areata patients 
(7) the expression in lesionai hair follicles of alopecia areata patients, of 
the intercellular adhesion molecule-1 (ICAM-1) is correlated with the 
presence of contiguous activated Τ cells20. 
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1.4 THERAPEUTIC MODALITIES 
The treatment of alopecia areata is difficult. Various therapeutic approaches have 
been used to induce remission in alopecia areata. The patchy form of alopecia areata 
has a high rate of spontaneous remission. In alopecia totalis and alopecia universalis 
the prognosis for spontaneous regrowth of hair is extremely poor, but still present. 
Although alopecia areata is a benign disorder that may cause major cosmetic and 
psychosocial effects, it is not life threatening. The management of alopecia areata 
deserves full medical attention as the psychosocial impact can be very substantial. 
Individuals with severe alopecia areata often require long-term treatment to maintain 
cosmetically adequate hair growth. Therefore, therapeutic approaches should be, 
both effective and safe for long-term use. 
Topical immunotherapy 
In this mode of treatment, a contact sensitization is induced and a mild contact 
eczema is maintained on the scalp by weekly applications of a potent contact 
allergen. From 1976 onwards dinitrochlorobenzene has been used21. In 1979, Kratka 
et al. found DNCB to be mutagenic by the Ames (Salmonella microsome) test22, and 
therefore, DNCB was replaced by diphenylcyclopropenone (DCP) and squaric acid 
dibutylester (SADBE)2324. 
The success percentage of the topical immunotherapy with DCP or SADBE has been 
investigated in numerous clinical studies and varies to some degree25 26 27. Patients 
are sensitized, with a 2% solution of the contact allergens DCP or SADBE dissolved 
in acetone, by application an area of approximately 50 cm2 on the scalp. A mild 
contact eczema is maintained by weekly applications of the contact allergen. The 
concentration is increased until a mild eczematous reaction is obtained, consisting of 
itching, erythema and mild scaling. In the beginning, treatment of one half of the 
scalp is recommended, until hair growth appears within the treated area; the contact 
allergen is then applied on the entire scalp. Mild itching, erythema and scaling are 
desired signs and symptoms of the allergic response. After sensitization, however, a 
vesicular reaction cannot always be avoided. Frequently an enlargement of regional 
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lymph nodes can be seen. Very sporadically urticaria or erythema multiforme-like 
reactions are present. 
Photochemotherapy 
UVA in combination with topical and oral psoralens is used in the treatment of 
alopecia areata. According to the literature the first clinical response was seen after 
20 to 40 sessions, with a maximum response being achieved within 1 year28 M 30. 
Cosmetic responses varied considerably in these studies; these were generally better 
in those patients with a patchy type alopecia areata and in those receiving total body 
irradiation. In contrast, Healy and Rogers showed in a retrospective study of 102 
cases, success rates similar to or less than those without treatment31. Side effects are 
nausea, pigmentary changes and following prolonged treatment there is an increased 
occurrence of skin cancers and cataracts. 
The mode of action of PUVA in alopecia areata is thought to be immunomodulatory. 
The number of Langerhans cells has been reported to decrease during treatment32, 
and the fraction of circulating helper Τ cells is likewise reduced in patients with 
psoriasis33. 
Systemic corticosteroids 
Very high doses of oral corticosteroids, might be effective if prescribed during 
prolonged time intervals. Such an approach might give rise to relative common 
systemic side effects such as diabetes, striae, acne, obesity, lenticular opacities, 
hypertension, osteoporosis, and suppression of the adrenals. After discontinuation of 
this therapy, most patients with a severe alopecia areata had worsening of the 
alopecia34 35 Э6 37. Long-standing alopecia areata and severe alopecia areata in general 
show a poor response. Obviously, a drug with serious side effects and fast posttreat-
ment relapse, is not the treatment of choice in a chronic benign disease such as 
alopecia areata. 
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Topical application of corticosteroids 
The results of topical application of corticosteroids are not to be considered as a 
great advantage in the treatment of alopecia areata. Pascher et al38 reported a 
placebo-controlled trial with 0.2% fluocinolone acetonide cream with promising 
results, but the study of Leyden et al39 with 2.5% dexamethasone did not show a 
lasting satisfactory response. Besides the minor therapeutic effect, side effects of 
topical steroids may occur, consisting of local folliculitis and acneiform eruptions at 
the site of treatment38. 
Intralesional corticosteroids 
Intralesional injections of corticosteroids in localized alopecia areata may result in 
rapid hair growth40 4I, but in severe alopecia areata the steroid effectiveness and 
practicality of this approach are much diminished and a satisfactory hair growth is 
exceptional. Possible side effects of intralesional steroids include transient subcu-
taneous and dermal atrophy. A perilymphatic atrophy of the skin42, has been 
reported, however this side effect is very rare. 
Minoxidil 
Minoxidil is a potent peripheral vasodilator for the treatment of severe hypertension. 
The results of topical minoxidil (1, 3 and 5%) in alopecia areata are disappointing43 
44 45 46 47 y n e treatment with oral minoxidil (5 mg twice a day), is of no benefit in 
severe alopecia areata, and it may have serious side effects, like sodium and fluid 
retention, facial hypertrichosis, palpitations and tachycardia45. 
Cyclosporin 
Cyclosporin is a potent immunosuppressive drug. Oral cyclosporin can be an 
effective treatment of alopecia areata, but side effects20, e.g. hypertension and 
impairment of renal function, may limit its use. Significant hair loss occurred in all 
patients within 3 months after discontinuation of treatment. 
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Cyclosporin inhibits the activation of Τ helper (CD4) cells, and enhances the Τ 
suppressor (CD8) cell activity. A significant decrease in the CD4/CD8 ratio has 
been reported early in the treatment and was maintained throughout the therapy, 
suggesting that cyclosporin may alter the balance of immunoregulatory lymphocytes 
around the hair follicles20. Topical cyclosporin (2%) did not result in a substantial 
hair regrowth48. 
Inosiplex 
Inosiplex, an investigational synthetic drug that has been shown to improve the 
function of Τ cells, monocytes and neutrophils, might act as a synthetic 
immunomodulator in alopecia areata. 
In a randomized double-blind study in alopecia areata totalis, Galbraith et al49 
demonstrated some regrowth of hair in eleven of twenty patients treated with 
inosiplex. Lowy et al50 showed a positive clinical response in nine of fourteen 
patients treated with inosiplex. 
Anthralin 
Anthralin cream, 0.5% and 1.0% was used in the treatment of alopecia areata. 
Twenty to 25 percent of the patients treated with these concentrations of anthralin 
showed some improvement51. Schmoeckel et al reported cosmetically good results in 
two of eight patients with alopecia areata totalis treated with anthralin52. Side effects 
of anthralin are staining, pruritus, erythema, scaling, folliculitis, local pyoderma, 
and regional lymphadenopathy. When the results of application of the irritant 
anthralin are compared with the application of a potent contact allergen, it is clear 
that topical immunotherapy is superior. 
Other therapies 
Various groups claimed efficacy of thymopentin, a synthetic pentapeptide that 
represents the active site of thymopoietin53 M. Topical nitrogen mustard has been 
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reported in one study to be of some therapeutic benefit55. The results of oral zinc are 
not consistent5657. 
Although all these treatment modalities have been advocated, the benefit of most of 
them is so far unproven. The most promising therapy is topical immunotherapy, 
followed by photochemotherapy. 
1.5 AIM OF THIS THESIS 
Although the results of earlier investigations may contain some 
contradictions, these studies generally suggest that cell-mediated immunity is a 
crucial factor in alopecia areata. However, several gaps in our understanding of 
alopecia areata have persisted. In particular, the role of epidermal proliferation, 
keratinization and expression of extracellular matrix molecules remains to be 
elucidated. 
A technical problem in studies of the hair follicles is the low quality of 
frozen sections of scalp biopsies. In order to process adequate sections from hair 
follicles within fatty tissue the preparation of frozen sections has to be carried out at 
considerable lower temperatures as compared to the temperatures of standard 
microtomes. In order to assess immunohistochemical changes quantitatively or 
semiqualitatively, transverse sections only will permit the assessment of a few hair 
follicles. Horizontal sectioning at the various levels is a methodology, which has to 
be developed for an adequate immunohistochemical assessment of hair follicles. 
Recently, monoclonal antibodies became available for the identification of 
recruited cycling cells from the resting G„ population. Recruitment of cycling 
epidermal cells, has so far not been analysed in normal and diseased hair follicles. A 
series of antibodies became available to study the process of epidermal 
keratinization. Recently the immunohistochemical assessment of various extracellular 
matrix molecules has been developed. A systematic analysis of recruitment of 
cycling cells, various keratins and extracellular matrix molecules in biopsies taken 
from normal skin and lesionai skin of alopecia areata, is so far not available. 
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Topical immunotherapy with diphenylcyclopropenone proved to be effective 
in the treatment of alopecia areata. The efficacy of topical immunotherapy in relation 
to the subtypes of alopecia areata, the value of prognostic factors, as inclusion 
criteria for the treatment need to be investigated. Recently the compound dapsone 
was claimed to reach the efficacy of topical immunotherapy. However, various 
groups indicated that their experience failed to confirm this effectiveness 
(unpublished data). 
In the light of the gaps described in the first part of this paragraph, the following 
aims were defined: 
I To describe recruitment of cycling epidermal cells, expression of keratins and 
extracellular matrix molecules in follicles of scalp biopsies from normal 
subjects and lesionai skin of patients with alopecia areata, using a new 
immunohistochemical approach. 
Π To further develop the most successful treatment of alopecia areata. 
In order to obtain further information on the pathogenetic processes involved 
in alopecia areata, the following issues were addressed: 
(i) Development of a suitable method for horizontal cryosectioning of 
hair follicles in fatty tissue (chapter 2). 
(ii) Analysis of the extracellular matrix proteins, tenascin, fibronectin, 
laminin and heparan sulphate proteoglycan in normal skin and lesionai 
skin of patients with alopecia areata (chapter 3). 
(iii) Analysis of recruitment of cycling epidermal cells (Ki-67 positive 
nuclei) and epidermal differentiation (various cytokeratins) in normal 
skin and lesionai skin of patients with alopecia areata (chapters 4 and 
5 resp.). 
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In order to extend our knowledge of immunotherapy of alopecia areata the 
following questions were addressed 
(IV) Evaluation of clinical efficacy and side effects of topical 
immunotherapy, with special reference to prognostic factors (chapter 
6) 
(v) Comparison of topical immunotherapy and dapsone with respect to 
clinical efficacy and side effects (chapter 7) 
REFERENCES 
1 Dawber RPR, Ebling FJG, Wojnarowska FT Disorders of hair In Rook A, 
Wilkinson DS, Ebling FJG, Champion RH, Burton JL eds Textbook of dermatolo­
gy 5th ed Oxford Blackwell Scientific Publications, 1992 2586-2595 
2 De Sauvages SFB Nosologia methodica sistens morborum classes juxta Sydenhami 
mentem et botanicorum, 7 Ordo no 38, alopecia, Amsterdam In Frabes de Tournes 
1768 
3 Nelson DA, Spielvogel RL Alopecia areata Int J Dermatol 1985,24 26-34 
4 Helm F, Milgrom H Can scalp hair suddenly turn white Arch Derm 1970,102 102-
103 
5 Gollnick H, Orfanos CE Alopecia areata pathogenesis and clinical picture In 
Orfanos CE, Happle R, eds Hair and Hair diseases Berlin Springer, 1990 529-569 
6 Walker SA, Rothman S Alopecia areata A statistical study and consideration of 
endocrine influences J Invest Dermatol 1950,14 403-413 
7 Muller SA, Winkelmann RK Alopecia areata An evaluation of 736 patients Arch 
Dermatol 1963,88 290-297 
8 Gip L, Lodin A, Molin L Alopecia areata A follow up investigation of outpatient 
material Acta Derm venereol 1969,49 180-188 
9 Steen van der Ρ, Traupe Η, Happle R et al The genetic risk for alopecia areata in 
first degree relatives of severely affected patients Acta Derm Venereol( Stockh) 
1992,72 373-375 
10 Carter M, Jegasothy BV Alopecia areata and Down syndrome Arch Dermatol 
1976,112 1397-1399 
11 Lever WF, Schaumburg-Lever G Histopathology of the skin 7th ed Philadelphia, 
JB Lippincot 1990 
12 Messenger Ag, Slater DN, Bleehen SS Alopecia areata alterations in the hair 
growth cycle and correlation with the follicular pathology Br J Dermatol 
1986,114 337-347 
13 Perret С, Brocker E, Wiesner-Menzel L, Happle R In situ demonstration of Τ cells 
in alopecia areata Arch Dermatol Res 1982,273 155-158 
14 Happle R, Klein HM, Macher E Topical immunotherapy changes the composition 
of the peribulbar infiltrate in alopecia areata Arch Dermatol Res 1986,278 214-218 
15 Brocker EB, Echtemacht-Happle K, Hamm Η, Happle R Abnormal expression of 
class I and class II major histocompatibility antigens in alopecia areata evidence that 
it is secondary to the lymphoid infiltration J Invest Dermatol 1986,88 564-568 
16 Messenger AG, Bleehen SS Expression of HLA-DR by anagen hair follicles in 
alopecia areata J Invest Dermatol 1985,85 569 572 
General Introduction 17 
17 Hamm H, Klemmer S, Kreuzer I, Steijlen PM, Happle R, Brocker EB HLA-DR 
and HLA-DQ antigen expression of anagen and telogen hair bulbs in long-standing 
alopecia areata Arch Dermatol Res 1988,280 179-181 
18 Wiesner-Menzel L, Happle R Intrabulbar and peribulbar accumulation of dendritic 
OKT 6-positive cells m alopecia areata Arch Dermatol Res 1984,276 333-334 
19 Perret С, Wiesner-Menzel L, Happle R Immunohistochemical analysis of T-cell 
subsets in the peribulbar and intrabulbar infiltrates of alopecia reata Acta Derm 
Venereol (Stockh) 1984,64 26-30 
20 Gupta AK, Ellis CN, Cooper KD et al Oral cyclosporine for the treatment of 
alopecia areata J Am Acad Dermatol 1990,22 242-250 
21 Happle R, Echternacht К Induction of hair growth in alopecia areata with DNCB 
Lancet 1977,11 1002-1003 
22 Kratka J, Goerz G, Vizethum W et al Dinitrochlorobenzene influence of the 
cytochrome P-450 system and mutagenic effects Arch Dermatol 1979,266 315-318 
23 Happle R, Büchner U, Kalveram KJ, Echtemacht-Happle К Contact allergy as a 
therapeutic tool for alopecia areata comparison between dinitrochlorobenzene and 
squanc acid dibutylester Arch Dermatol 1979,264 101-102 
24 Happle R, Hausen BM, Wiesner-Menzel L Diphenylcyprone in the treatment of 
alopecia areata Acta Derm Vener (Stockh) 1983,63 49-52 
25 MacDonald-Hull S, Cunliffe WJ Successful treatment of alopecia areata using the 
contact allergen diphencyprone Br J Dermatol 1991,124 212-213 
26 Ochsendorf FR, Mitron G, Milbradt R Treatment of alopecia areata with 
diphenylcyclopropenone Ζ Hautkr 1988,63 94-100 
27 Orecchia G, Rabbiosi G Squanc acid dibutylester in alopecia areata is discomfort 
really necessary J Am Acad Dermatol 1987,16 876 
28 Lassus A, Kianto U, Johansson E, Juvakoski Τ PUVA treatment for alopecia 
areata Dermatologica 1980,161 298-304 
29 Claudy AL, Gagnaire D PUVA treatment of alopecia areata Arch Dermatol 1983, 
119 975-78 
30 Van der Schaar WW, Smitt JHS An evaluation of PUVA-therapy for alopecia 
areata Dermatologica 1984,168 250-252 
31 Healy E, Rogers S PUVA treatment for alopecia areata- does it work'' A retrospec­
tive review of 102 cases Br J Dermatol 1993,129 42-44 
32 Merk NJ, Gaudernack G, Braathen LR Effect of UVA and PUVA on allo-activating 
and antigen-presenting capacity of human epidermal Langerhans cells 
Photodermatology 1987,4 66-72 
33 Moscicki RA, Morison WL, Parnsh JA et al Reduction of the fraction of circulat­
ing helper-inducer Τ cells identified by monoclonal antibodies in psoriatic patients 
treated with long-term psoralen ultraviolet-Α radiation (PUVA) J Invest Dermatol 
1982,79 205-208 
34 Kern F, Hoffman WH Alopecia areata Immunologic studies and treatment with 
prednisone Arch Dermatol 1973,107 407-412 
35 Winter RJ, Kern F, Blizzard RM Prednisone therapy for alopecia areata A follow-
up report Arch Dermatol 1976,112 1549-1552 
36 Unger WP, Schemmer RJ Corticosteroids in the treatment of alopecia totalis Arch 
Dermatol 1978,114 1486-1490 
37 Burton JL, Shuster S Large doses of glucocorticoid in the treatment of alopecia 
areata Acta Dermatovener (Stockholm) 1975,55 493-496 
38 Pascher E, Kurtin S, Andrade R Assay of 0 2% fluocinolone acetonide cream for 
alopecia areata and totalis Efficacy and side effects including histologic study of the 
ensuing localized acneform response Dermatologica 1970,141 193-202 
39 Leyden JJ, Kligman AM Treatment of alopecia areata with steroid solution Arch 
18 Chapter 1 
Dermatol 1972; 106:924. 
40 Abell E, Munro DD. Intralesional treatment of alopecia areata with triamcinolone 
acetonide by jet injector. Br J Dermatol 1973;88:55-59. 
41 Frentz G. Topical treatment of extended alopecia. Intralesional steroid-Kromayer 
lamp. Dermatologica; 155:147-154. 
42 Kikuchi I, Horikawa S. Perilymphatic atrophy of the skin. Arch Dermatol 
1975;111:795-796. 
43 Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in 
extensive alopecia areata. J Am Acad Dermatol 1987;16:730-736. 
44 Price VH. Topical minoxidil (3%) in extensive alopecia areata, including long-term 
efficacy. J Am Acad Dermatol 1987;16:737-44. 
45 Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of 
alopecia areata. J Am Acad Dermatol 1987;16:745-8. 
46 White SI, Friedmann PS. Topical minoxidil lacks efficacy in alopecia areata. Arch 
Dermatol 1985;121:591. 
47 Frentz G. Topical minoxidil for extended areate alopecia. Acta Derm Venereol 
(Stockh) 1985;65:172-175. 
48 De Prost Y, Teillac D, Paquez F, et al. Placebo-controlled trial of topical 
cyclosporin in severe alopecia areata. Lancet 1986;11:803-804. 
49 Galbraith GM, Thiers BH, Jensen J et al. A randomized double-blind study of 
inosiplex (Isoprinosine) therapy in patients with alopecia totalis. J Am Acad 
Dermatol 1987;16:77-83. 
50 Lowy M, Ledoux-Corbusier M, Achten G, Wybran J. Clinical and immunologic 
response to Isoprinosine in alopecia areata and alopecia universalis: association with 
autoantibodies. J Am Acad Dermatol 1988;12:267-274. 
51 Fiedler-Weiss VC, Buys CM. Evaluation of anthralin in the treatment of alopecia 
areata. Arch Dermatol 1987;123:1491-1493. 
52 Schmoeckel C, Weissmann I, Plewig G, Braun-Falco O. Treatment of alopecia 
areata by anthralin-induced dermatitis. Arch Dermatol 1979;115:1254-1255. 
53 Tosti A, Manuzzi P, Gasponi A. Thymopentin in the treatment of severe alopecia 
areata. Dermatologica 1988;177:170-174. 
54 Orecchia G. Thymopentin in the treatment of alopecia areata. Dermatologica. 1989; 
178:231. 
55 Arrazola JM, Sendagorta E, Hart A, Ledo A. Treatment of alopecia areata with 
topical nitrogen mustard. Int J Dermatol 1985;24:608-610. 
56 Ead RD. Oral zinc sulphate in alopecia areata: a double blind trial. Br J Dermatol 
1981; 104:483^84. 
57 Wolowa F. Behandlung von Alopecia areata totalis und maligna mit Solvezink. Ζ 
Hautkr 1982;57:393Ч05. 
General Introduction 19 

Chapter 2 
CRYOSECTIONING OF HAIR FOLLICLES 
AN IMPROVED METHOD USING LIQUID NITROGEN 
CONDUCTION FREEZING 
H.M.J, van Baar, J. Schalkwijk and CM. Perret 
Department of Dermatology, University Hospital Nijmegen, Nijmegen, 
The Netherlands. 
Acta Derm Venereol (Stockh) 1990;70:335-338 

SUMMARY 
Horizontal sectioning of scalp biopsies is especially useful in hair diseases character­
ized by a reduction of follicles in size or number. Horizontal sectioning using 
standard cryo-microtomes is hampered by the differences in cutting properties 
between hair follicles and fatty tissue, resulting in loss of topography. We report a 
simple, inexpensive method to temporarily cool the specimen to an appropriate 
temperature by means of a conduction system using liquid nitrogen. Immunohistolo-
gical methods such as immunofluorescence and immunoperoxidase techniques can be 
applied without restrictions. 
INTRODUCTION 
For routine histopathology and immunohistological analysis vertical skin sections are 
used. For hair diseases a better approach would be the use of horizontal sections. 
The practical value of this approach in frozen sections is limited due to the 
difference in the optimal cutting temperature for hair follicles and connective or fatty 
tissue. The optimal temperature for cutting fatty tissue is below -30°C and thus 
beyond the range of standard laboratory cryo-microtomes. 
We report a simple, inexpensive method for cooling the biopsy on the tissue 
holder to an appropriate temperature by means of a conduction system using liquid 
nitrogen. By using this technique, sections similar in quality to paraffine sections can 
be obtained. In order to show that the expression of common antigens is not altered, 
the sections were processed with standard techniques for immunofluorescence and 
immunoperoxidase staining. In normal hair follicles, the expression of cytokeratin 
13/16 was analysed. In order to evaluate this approach in hair diseases, we chose 
alopecia areata as a disorder with a prominent Τ cell infiltrate12 for staining with an 
antibody with anti-CD2 reactivity. 
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MATERIALS AND METHODS 
Liquid nitrogen conduction freezing 
The conduction system consists of an aluminium vial ( diameter of 30 mm, height of 
29 mm) normally used as a specimen vial for the storage of frozen biopsies (Sanbio, 
Uden, The Netherlands). It is closed with a screw cap, in which some holes of 
approx. 2 mm are drilled. For better handling, a long screw is fixed in the middle of 
the top (Fig. 1). The entire system can be filled by dipping it in a reservoir with 
liquid nitrogen. The bottom of the vial is pressed on the tissue specimen lightly, in 
order to cool it to the appropriate temperature. 
••-.j.'" 
4— handle 
4_ hole 
4— handle 
4 _ cover 
4 _ aluminium vial 
4— biopsy 
·«— tissue holder 
Fig. 1. Liquid nitrogen conduction freezing system. 
A. Lateral view. 
B. View from the top. Note filling holes. 
C. Insert: photograph of the system. 
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Calibration procedure 
The optimal conditions for the conduction freezing process were determined 
experimentally, using a temperature-sensitive resistor (thermistor YSI 409 A, 
Tamson, Zoetermeer, The Netherlands) embedded in a block of Tissue-Тек (approx. 
l x l x l cm), mounted on the tissue holder of the cryostat (set at -25°C). The 
thermistor had first been calibrated in the range from -20°C (18 Ш) to -115°C (19 
ΜΩ): a linear curve was obtained by plotting the logarithm of the electrical 
impedance against the temperature. An application time of 20 seconds was found to 
be sufficient to equilibrate the block of Tissue-Тек with the liquid nitrogen. After 
removing the liquid nitrogen vial from the block, the time required to reach -40°C 
(80 кП) was recorded, since this is the highest temperature which allows proper 
sectioning of adipose tissue (Fig. 2). Following this method it was found that 
sections could be obtained up to 25-30 seconds after removal of the liquid nitrogen. 
This allows 5 to 7 high quality sections to be taken. Excessive pressure of the 
aluminium vial on the tissue should be avoided to prevent damaging of the first 
section. 
time available for cryosectioning (sec) 
25 - , 
20 -4- , - - - " 
ι / 
16 - -
\ 
10 - / 
5 -
0 10 20 30 40 
conduction system application time (sec) 
Fig. 2. Relation between conduction system application time and time available for cryo­
sectioning. 
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Biopsies 
Excisional scalp biopsies were taken from controls and from the margins of active 
lesions of patients affected with alopecia areata for routine HE-staining and 
immunophenotyping with the monoclonal antibodies K
s
8.12 (specific for cytokeratin 
13 and 16)3 4, and Ti l (anti-CD2 antibody). All biopsies were immediately 
embedded in Tissue-TEK II OCT Compound (Miles Inc., Diagnostics Division, 
Elkhart, Ind., U.S.A.), snap frozen in liquid nitrogen and stored at -80°C until use. 
The specimens were sectioned at 5 μπι in a 2800 Frigocut-N cryostat (Reichert-Jung, 
Cambridge Instruments GmbH, Nußloch, FRG). Routine hematoxylin-eosin (H.E.) 
staining was performed. 
Immunohistology 
For immunofluorescence, an indirect immunofluorescence technique according to 
Ramaekers et al.5 was used. Aceton-fixed sections 5 μιη thick, were investigated for 
the presence of cytokeratin 16 using K,8.12 (dilution 1/20, Sigma Chemical Comp­
any, St. Louis, MO., USA) and FITC-conjugated goat anti-mouse IgG (dilution 
1/25, Tago, Burlingame, CA, USA). 
Immunostaining for T-lymphocytes was performed using a monoclonal anti-
CD2 antibody (Til dilution 1/100, Dakopatts, Glostrup, Denmark) with the 
peroxidase - antiperoxidase (PAP) technique6. The sections were examined using a 
Zeiss photomicroscope. 
RESULTS 
Evaluation of the conduction freezing system 
Fig. 3 illustrates the results of different staining procedures on sections obtained by 
the method described above. In Figs. 3a, b, the results of H.E. staining of sections 
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obtained by the method described above are shown. The left hair follicle in Fig. 3a 
is cut in the lower third of the hair bulb. The connective tissue of the papilla is 
clearly visible, surrounded by matrix cells separated from the papilla by mucinous 
stroma. The hair follicle on the right is cut above the line of Auber, just at the top 
of the papilla. The most proximal part of it can just be seen. The matrix cells do not 
show differentiation at this stage. Both hair bulbs are surrounded by a thin sheath of 
connective tissue, entirely located in fatty tissue, which is well preserved. Fig. 3b 
shows the hair follicle sectioned in the transition zone between fatty tissue and 
dermis. Differentiation is already advanced. 
In order to analyse an inflammatory infiltrate, sections of the active margin 
of alopecia areata lesions were stained with the monoclonal antibody Ti l , which 
recognizes the CD2-antigen present on the majority of Τ cells. Fig. 3c demonstrates 
a well preserved hair follicle, at the level of the matrix, located in fatty tissue. A 
dense peribulbar infiltrate shows membrane staining for CD2. 
To show that the detection of structural proteins remains unchanged, indirect 
immunofluorescence staining cytokeratin 16 using the monoclonal antibody K,8.12 
(with specificity for cytokeratin 13 and 16) was performed. Fig. 3d illustrates that 
the application of the conduction technique allows immunostaining of cytokeratin 16 
without problems. The section is cut at the level of the matrix. The matrix cells are 
negative, whereas the epithelial root sheath, which is not yet differentiated at this 
level, shows marked immunofluorescence. Controls were negative. 
DISCUSSION 
Immunohistological staining of hair follicle structures in general requires the use of 
frozen sections. Since in many hair diseases the hair follicles may be reduced in 
number or size, serial sections are needed to obtain an overall view. Furthermore, as 
hair follicles are not orientated perpendicular to the skin surface, but at various 
angles, sections containing follicles throughout their length are difficult to obtain. 
Due to the different angles, a proper orientation is only possible for one or few 
follicles, the others being orientated in another direction. 
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Fig. 3. Staining of frozen sections of hair follicles: 
(A) H.E. staining of transverse sections through the hair bulb. Note connective tissue 
papilla in the left bulb, surrounded by mucinous stroma and hair matrix cells. Folli-
cle on the right cut just at the top of the hair bulb. 
(B) H.E. staining of a hair follicle located at the border between fatty tissue and dermis. 
The following structures can be differentiated: in the centre the cornified cells of the 
hair, already without nuclei, can be seen. This layer is followed by the inner root 
sheath, even the subdivision in different layers can be distinguished. The outer root 
sheath is fully differentiated and surrounded by a layer of connective tissue. 
(C) PAP staining of the peribulbar infiltrate in alopecia areata with the anti-CD2 
antibody Ti l . 
(D) Indirect immunofluorescence with the monoclonal antibody Ks8.12 showing positive 
immunofluorescence of the not yet differentiated root sheath at the level of the hair 
matrix. 
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Horizontal sectioning of scalp tissue overcomes most of these problems. However, 
this approach is limited by the fact that the hair bulbs are usually located in the fatty 
tissue, which causes difficulties in obtaining cryosections due to the differences in 
the physico-chemical properties of fatty tissue and hair bulb keratinocytes. With the 
conduction system described above, these problems can be overcome with minimum 
expense and without the need to adapt standard protocols for immunohistochemical 
staining. We could show that different types of antigens like intracellular polypepti­
des such as the cytokeratins can be demonstrated, as well as membrane-bound 
antigens such as Τ cell surface markers, without a detectable loss of quality. We feel 
that this method will become a valuable tool for the study of hair diseases. 
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SUMMARY 
Tenasciii, a recently discovered extracellular matrix protein, was demonstrated in 
perifollicular connective tissue of normal human scalp using immunohistochemistry 
Its localization was different from other well-known extracellular matrix 
components, like fibronectin, laminin and heparan sulphate proteoglycan A 
comparison between alopecia areata and normal scalps did not reveal major 
qualitative differences, except for an increased expression near heavily infiltrated 
follicles 
INTRODUCTION 
Extracellular matrix (ECM) components such as fibronectin, laminin and tenascin 
are known to play an important role in the development and differentiation of cells 
in many tissues1 Various processes, such as migration, proliferation and 
differentiation of epithelial cells, are directed by ECM molecules via interaction with 
specific receptors, the mtegrins2 It is known that the epithelial-mesenchymal 
transformation can be influenced by the extracellular matrix The presence of 
laminin, fibronectin, and heparan sulphate proteoglycan is well established in many 
tissues including human skin3 4 5 
Tenascin, a recently discovered large oligomenc glycoprotein of the 
extracellular matrix (also known as myotendmous antigen6, hexabrachion7, glial 
mesenchymal extracellular matrix antigen8 and cytotactin9) was shown to be present 
in human skin and some of the adnexal structures such as sweat gland ducts10 " The 
function of tenascin in skin has not yet been elucidated Individual studies have 
concentrated on distinct tissues and tissue interactions, including dense connective 
tissue, central nervous system, epithelial-mesenchymal interfaces of embryos and 
tumour matrix Several characteristics have been described indicating that tenascin 
plays a role more in the maintenance of the epidermal histogenesis than as a 
structural component 
There is little information on the distribution of tenascin in human hair 
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follicles. In this paper we describe the expression of tenascin in human perifollicular 
connective tissue, and we compare this protein with other structural ECM molecules 
such as fibronectin, laminin and heparan sulphate proteoglycan. In addition, the 
expression of ECM molecules in normal scalp was compared with alopecia areata. 
MATERIALS AND METHODS 
Biopsies 
Excisional scalp biopsies were taken from healthy controls and from the margins of 
active lesions of patients suffering from alopecia areata. All biopsies were 
immediately embedded in Tissue-Tek II Compound (Miles Inc., Diagnostics 
Division, Ind., Elkhart, USA), snap frozen in liquid nitrogen and stored at -80°C 
until further use. Sections (5 /tm) were cut using a 2800 Frigocut-N cryostat 
(Reichert-Jung) at -28"C12. The sections were placed on bovine serum albumin 
coated slides, air-dried for at least 30 min and then fixed with acetone for 10 min 
and stored in sealed boxes at -80°C until use. Fixation in paraformaldehyde (4% in 
PBS) for 30 min is not recommended, since it destroys most of the tenascin 
reactivity. 
Antisera 
Antiserum against tenascin purified from rat embryo fibroblast cultures was raised in 
rabbits as previously described13. The serum was absorbed on a fibrinogen-Sepharose 
4B column and specificity was checked by Western blot analysis and enzyme-linked 
immunoadsorbent assay. No reactivity against fibronectin and fibrinogen, to which 
there is homology"11516 could be detected. The antiserum was found to react with 
human tenascin produced by Saos-2 osteosarcoma cells, as described previously11. In 
addition, a rabbit antiserum against tenascin from chick fibroblasts was used. The 
details on specificity have been published elsewhere17 u . Both antisera showed 
identical staining patterns in all tissues examined. 
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A monoclonal antibody (JM-72) to heparan sulphate core protein was kindly 
supplied by J. van den Born, Department of Nephrology, University Hospital 
Nijmegen. It was raised using human glomerular basement membranes to immunize 
BALB/c mice. Spleen cells were fused with Sp2/0 cells according to standard 
protocols. Ascites fluid was used at a 1:500 dilution. 
Anti-laminin serum was obtained by immunizing a rabbit with mouse laminin 
from Englebreth-Holm-Swarm mouse tumor cells. The antiserum was found to 
cross-react with human laminin. 
Monoclonal antibody to human plasma fibronectin was obtained from Sigma 
Chemical Co., St. Louis, Mo., USA (clone F7387, ascites fluid). 
Immunohistology 
The immunoperoxidase staining was performed as follows: the fixed sections were 
rehydrated with PBS for 3 min, then incubated with antisera diluted in PBS (1:200 
for antitenascin, 1:500 for antifibronectin, 1:10 for antilaminin and 1:500 for 
antiheparan sulphate proteoglycan) in a humidified chamber at room temperature for 
30 min (antifibronectin 1 h). After washing in PBS, sections were incubated either 
with peroxidase conjugated rabbit anti mouse Ig or swine anti rabbit Ig (Dakopatts, 
Glostrap, Denmark) in a dilution 1:100 in PBS with 5% normal human AB serum 
for 60 min at room temperature. After washing with PBS, the sections were 
preincubated with sodium acetate buffer (pH 4,9) and finally stained with 3-amino-9-
ethylcarbazole solution (Sigma) and H202 for 10 min at room temperature in the 
dark. After two washes with demineralized water the sections were counterstained 
with Mayer's haematoxylin solution (Sigma) and mounted in glycerin-gelatin. The 
sections were examined using a Zeiss photomicroscope. 
RESULTS 
Tenascin expression in human scalp 
Tenascin expression was examined in five normal scalp biopsies and in five active 
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lesions of alopecia areata using rabbit anti-rat tenascin serum, followed by 
immunoperoxidase staining. In normal scalp, tenascin expression can be found in the 
connective tissue papilla of the hair and the perifollicular connective tissue sheath. In 
anagen, tenascin is localized at the base of the dermal papilla of the hair follicle. 
The staining pattern of the dermal papilla is not homogeneous being most 
pronounced at the top and the bottom (Fig. 1). In horizontal sections of normal 
scalp, tenascin staining of anagen hair follicles in the fatty tissue appears as a well-
delineated sheath (Fig. 2). The tenascin expression during the development of 
anagen follicles (stage I-VI) does not change. In contrast, in telogen hair follicles the 
expression is reduced. The earliest point of occurrence is at the development of the 
dermal papilla. 
Fig. 1. Immunoperoxidase staining of a normal anagen hair follicle with anti-tenascin. 
Staining of the connective tissue sheath is intense (arrows), but the staining at the 
level of the top of the dermal papilla is less pronounced (arrowhead). Note positive 
staining of the base and the top of the dermal papilla. The granular staining in the 
centre of the dermal papilla is due to melanin. (Original magnification χ 60) 
Fig. 2. Tenascin staining of horizontally cut hair follicles (normal scalp) shows strong well-
delineated staining of the connective tissue sheath (arrows). (Original magnification 
χ 150) 
36 Chapter 3 
Tenascin expression can also be observed in other dermal structures such as 
the arrector pilorum muscles and the epineurium of the nerves (not shown). Tenascin 
staining of the sweat glands of the scalp was limited to the ductal portions, as has 
been described for normal trunk skin10. In normal scalp, tenascin is also localized at 
the dermo-epidermal junction with staining of a small dermal zone (not shown). 
The distribution of tenascin in scalp biopsies of patients suffering from 
alopecia areata was similar to that in normal scalp except for some quantitative 
differences in expression. In active alopecia areata lesions, almost exclusively 
containing telogen hairs, tenascin was expressed in a more diffuse and irregular 
pattern compared to anagen hairs (Fig. 3). Near anagen hair follicles showing a 
dense mononuclear infiltrate, a strong expression of tenascin was observed 
throughout the infiltrated connective tissue (Fig. 4). 
Fig. 3. Tenascin staining in active alopecia areata, containing almost exclusively telogen hair 
follicles. Tenascin is expressed in a diffuse and irregular pattern (arrows). (Original 
magnification χ 150) 
Fig. 4. Anagen hair follicle from an active alopecia areata lesion with a dense mononuclear 
infiltrate. Note the pronounced but diffuse tenascin staining in the perifollicular 
connective tissue. (Original magnification χ 60) 
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Expression of fibronectin, laminili and heparan sulphate proteoglycan 
Three other ECM molecules (fibronectin, laminin and heparan sulphate 
proteoglycan) were studied to compare their distribution with tenascin expression in 
human scalp. 
Fibronectin was found in the dermal papilla, glassy membrane and connective 
tissue sheath associated with follicular epithelium, as already shown previously for 
the rat19. The expression of laminin and heparan sulphate proteoglycan is limited to 
the basement membranes and the dermal papilla (Figs. 5 and 6). The expression 
patterns of the distinct ECM components, associated with anagen follicles, are 
summarized in Table 1. 
Fig. 5. Heparan sulphate proteoglycan staining of hair follicles sectioned horizontally 
(normal scalp). Basement membranes of the hair follicles {arrows) show positive 
staining. E, eccrine sweat glands; A, arrector pili muscle. (Original magnification χ 
200) 
Fig. 6. Heparan sulphate proteoglycan staining of the telogen hair follicle surrounded by 
blood vessels. Note the irregular basement membrane (arrows) compared with 
anagen hair follicles (Fig. 5) (Original magnification χ 200) 
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Table 1. Expression pattern of different ECM components 
Structure 
Hair (anagen) 
Dermal papilla 
Inner root sheath 
Outer root sheath 
Glassy membrane 
Connective tissue sheath 
Dermo-epidermal junction 
Sebaceous gland 
M arrector pili 
Eccnne sweath gland 
Blood vessels 
Nerves 
Fatty tissue 
Tenascin 
+' 
-
-
+ 
+ +b 
+ + 
-
+ 
+d 
+ + 
+e 
-
Fibronectin 
+ + 
-
-
+ 
+b 
+ 
-
+ + 
+d 
+ + 
+ 
-
Laminm 
+ + 
-
-
+b 
-
+ + 
+c 
+ 
+c 
+c 
+ 
+ 
Heparan 
sulphate 
proteoglycan 
+ + 
-
-
+ + 
-
+ + 
+c 
+ 
+c 
+c 
+ 
-
+ , weak stainmg, + + strong staining 
a
 Diffuse, not homogeneous staining 
b
 Stage dependent staining pattern 
c
 Basement membrane staining 
" Ductuli +, cells-
e
 Epineunum 
DISCUSSION 
Extracellular matrix components are major factors in the maintenance and develop-
ment of the skin architecture In addition to providing mechanical strength, they play 
a prominent part in processes such as differentiation, migration and growth 
Tenascin is known to be present in conditions showing interaction of mesenchyme 
with proliferating epithelium13 Tenascin was found selectively associated with the 
mesenchyme immediately surrounding the epithelium, as observed in hair follicles, 
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during early embryogenesis in the rat18. Recently, the presence of tenascin in normal 
skin of rats13 and humans10 was reported. In normal rat skin, there was strong 
tenascin staining of the large sensory vibrissa hair follicles and of the epidermal 
pads, the area of thickened epidermis associated with vibrissa follicles. 
In this study we found abundant tenascin expression associated with anagen 
hair follicles. The persistence of tenascin observed near telogen hair follicles, and 
the weaker expression of tenascin at the upper bulb below the keratogenous zone, 
could be caused by slow turnover, resulting in diffuse localization. The sharply 
demarcated tenascin expression around anagen hair follicles could be interpreted as 
de novo synthesis induced by proliferative keratinocytes. However, the relationship 
of tenascin expression with the hair growth cycle remains a subject for further 
investigation. 
The expression of fibronectin and laminin has been documented for rat hair 
follicles, where a cyclic variation pattern was found in synchrony with the hair 
cycle19. No data exist in the literature regarding the expression of heparan sulphate 
proteoglycan, comparing anagen and telogen hair follicles. Although the expression 
of some ECM molecules was shown to vary in accordance with the hair growth 
cycle, their functional role is not fully understood. Fibronectin plays a part in 
growth control and migration of both epithelial and mesenchymal cell types18. 
Laminin has a functional role in cell attachment and differentiation20, and it is 
important for the basement zone integrity before and during epidermal and follicular 
maturation21. The distribution of laminin during the hair growth cycle indicates that 
the extracellular matrix synthesis at this time is more intimately involved with 
epithelial cell movement, morphological change and connective tissue formation in 
the dermal papilla than with growth per se19. 
In rat embryos, during the development of hair follicles, heparan sulphate 
proteoglycan was associated with the basal cell layer prior to the appearance of hair 
follicle primordia, and became basement membrane zone associated before birth but 
after follicle buds were observed. Heparan sulphate proteoglycan was also found to 
be associated with the basal cell surfaces in the epidermis, but not in the hair 
follicle21. Heparan sulphate proteoglycan probably plays a part in the attachment of 
cells to basement membranes. 
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When we compare the expression pattern of tenascm found in normal scalp 
with that of fibronectin and basement membrane components (laminin and heparan 
sulphate proteoglycan), a number of differences can be observed, as shown in 
Table 1 
Comparing the ECM components in normal scalp skin with alopecia areata 
skin, the expression of laminin in hair follicles in alopecia areata was weak and 
sometimes totally lacking, in accordance with the findings of Gollnick et a l г г For 
the other ECM components such as tenascin, fibronectin and heparan sulphate 
proteoglycan, no large differences were found The dermis, containing the 
perifollicular infiltrate, shows a diffuse distribution of tenascin and fibronectin The 
variation of the expression of the distinct ECM components during the hair growth 
cycle mdicates that the synthesis of ECM components is intimately involved with 
epithelial cell migration, morphological change and connective tissue formation of 
the dermal papilla 
Although there are differences between the expression of distinct ECM 
components, only minor differences between alopecia areata and normal scalp skin 
were found In actively infiltrated alopecia areata lesions, an increased expression of 
tenascin was found However, this probably represents a reactive pattern rather than 
a disease-specific phenomenon, since it was not observed m alopecia areata without 
substantial infiltrate 
We conclude that, in general, alterations in connective tissue composition do 
not play a prominent part in the pathogenesis of alopecia areata 
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SUMMARY 
The monoclonal antibody Ki-67 was used to determine the numbers of cycling cells 
in hair follicles both in alopecia areata and in normal scalp skin. Pronounced nuclear 
staining was limited to the area below the critical line of Auber and the exterior part 
of the outer root sheath. In alopecia areata there is a reduced nuclear Ki-67 binding 
in the bulb of anagen hair follicles. These findings indicate that inhibition of 
keratinocyte proliferation might be a pathogenetic mechanism in alopecia areata. 
INTRODUCTION 
The proliferative state of cell populations in hair follicles is a major factor in the 
regulation of hair growth. The relative numbers of proliferating cells, i.e. the 
growth fraction, strongly influences hair growth. In vivo measurement of the growth 
fraction, e.g., by [3H]-thymidine of I-deoxyuridine labelling1 2 3, is difficult for 
obvious reasons. By using the monoclonal antibody Ki-67, a simple and rapid 
estimation of the growth fraction of a given human cell subset has become possible4. 
If a cell shows nuclear binding of this monoclonal antibody, the cell has passed the 
Gi-restriction point and is regarded as belonging to the cycling cell population; if a 
cell shows cytoplasmatic staining without nuclear binding, it is regarded as 
belonging to the resting (G0) population5. 
A disturbance in the proliferation rate of follicular stem-cells has been 
suggested to be of pathogenetic significance in alopecia areata. The purpose of the 
present study was to compare the growth fraction in keratinocyte populations of 
normal and alopecia areata hair follicles. 
We used both transverse and vertical sections of anagen and telogen hair 
follicles in alopecia areata lesions and normal scalp, to evaluate the Ki-67 binding. 
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METHODS 
Biopsies 
Excisional scalp biopsy samples were taken from healthy individuals free from a 
history of alopecia areata, and from the margin of active lesions of patients suffering 
from alopecia areata. All biopsies were immediately embedded in Tissue-Tek II 
Compound (Miles Inc., Diagnostic Division, Elkhart, Ind., USA), snap-frozen in 
liquid nitrogen and stored at -80°C until further use. Biopsies were processed as 
described elsewhere6. 5 μιη sections were cut using a 2800 Frigocut-N cryostat 
(Reichert-Jung) at -28°C. The cryostat sections were placed on slides coated with 
bovine serum albumin. The cryostat sections were air-dried for at least 30 min 
before fixing in acetone for 10 min and then stored in sealed boxes at -80°C until 
use. 
Histological grading 
On biopsies from 5 patients with alopecia areata and 5 normal controls, transverse 
serial sectioning was performed as described earlier6. These sections were 
subdivided into different sample-regions, namely: subcutaneous fat, transition 
between subcutaneous fat, non-papillary dermis and the papillary dermis. From each 
sample region, two sections were investigated. The anagen hair follicle was divided 
in five levels as shown in Fig. 1. Every hair follicle observed in a transverse section 
was classified as belonging to one of these five levels. The number of positive Ki-67 
nuclei of the hair follicle were counted in each section. Vellus hairs were excluded. 
Immunohistology 
Before use, the sections were placed in acetone-ether (60/40 v/v%) for 10 min. 
Thereafter the sections were placed in Tween-80 (0,01 %) for 3-5 min. 
Subsequently, the sections were incubated for 30 min at room temperature in a moist 
chamber with Ki-67 (Dakopatts, Copenhagen, Denmark), diluted 1:20 in PBS, 
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washed with PBS and subsequently incubated for 30 min with a peroxidase-
conjugated rabbit anti-mouse antibody (Dakopatts) at a dilution of 1:25 in PBS 
containing 5% human AB serum. After being washed with PBS, the bound 
peroxidase was developed with the 3-amino-9-ethylcarbazole/hydrogen peroxide 
reaction for 10 min. Finally the sections were rinsed in distilled water and 
counterstained with haematoxylin, and mounted in glycerin gelatin. The number of 
positive nuclei was counted per hair follicle at different stages, as observed in 
transverse sections. 
Fig. 1. Schematic representation of a an anagen hair follicle. 
level 1 
level 2 
level 3 
level 4: 
level 5: 
Hair bulb at the level of the centre of the dermal papilla. 
The suprabulbar area. 
Level below the sebaceous gland, in which the hair shaft is surrounded by 
partially keratinized inner root sheath, enclosed by the outer root sheath. 
Level below the sebaceous gland, showing a fully keratinized inner root 
sheath. 
Infundibulum. 
Statistics 
All variance analysis was done with GLM and NPARIWAY procedure of the S.A.S. 
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software Statistical package. 
RESULTS 
The results are summarized in Table I and in Figs. 2A-E. 
The Ki-67 positivity is significantly influenced by the level in the hair follicle 
(p < 0.001, Kruskal-Wallis test), though this is largely due to level 1, whereas the 
other levels showed no marked differences (Waller-Duncan grouping, ce = 0.05). 
Ki-67 positivity in alopecia areata is not significantly different from that of normal 
scalp, if we ignore the level of the follicle (pooled data from all levels (Mann-
Whitney test ρ > 0.1). 
Table I. Кі-67-positive nuclei per transverse section of the hair follicle in different stages; 
all values are presented as means ± SEM; η = number of follicles studied. 
Level 
1 
2 
3 
4 
5 
и 
14 
56 
45 
229 
10 
Normal scalp 
120+14 
20±3 
27±1 
15±1 
7±1 
η 
13 
23 
15 
123 
63 
Alopecia areata 
82±8 
11±3 
12±3 
11±1 
21±2 
However, when the level is taken into account, alopecia areata shows a dramatic 
decrease in Ki-67 positivity at level 1-4 (analysis of variance, ρ < 0.001). 
Interestingly, at level 5 (the subepidermal level of the follicle) the number of Ki-67-
positive nuclei in alopecia areata is significantly greater than in normal scalp skin. 
No quantitative data on telogen follicles and vertical sections of anagen hairs 
are given because only a limited number of the follicles per biopsy can be examined 
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in a vertical section. 
In addition, the pattern of Ki-67 is shown, in a vertical section of an anagen 
hair follicle (Fig. 3). Most of the positive nuclei are located below the critical line of 
Auber (i.e., the widest point of the dermal papilla, approximately at its midpoint)7. 
Late anagen hairs show hardly any Ki-67 positive nuclei (Fig. 4) at the 
matrix-level. In the telogen hair follicles (Fig. 5) there was no positive staining at 
any level. 
Fig. 2: Transverse sections of normal adult scalp. Immunoperoxidase staining with the 
monoclonal Ki-67 (Original magnification χ 63 in all figures). 
(A) Level 1 : Immunoperoxidase staining of the hair bulb of an anagen hair follicle using 
Ki-67, showing positive nuclear Ki-67 staining around the dermal papilla. 
(B) Level 2: Suprabulbar part of an anagen hair follicle, showing in the outer root sheath 
some positive nuclear Ki-67 staining. 
(C) Level 3: The hair shaft is surrounded by the inner root sheath, which is not fully 
keratinized. Note the positive Ki-67 nuclei localized mainly in the outer part. 
(D) Level 4: The hair shaft is surrounded by a fully keratinized inner root sheath. The 
outer root sheath contains the Ki-67 positive nuclei. 
(E) Level 5: Follicular infundibulum of bigeminy hair follicle. Note the positive Ki-67 
nuclei localized in the external part of the outer root sheath. 
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Fig. 3. Vertical section of an early anagen Fig. 4. Vertical section of a late anagen hair 
hair bulb, showing most of the Кі-67-positive bulb showing absence of positive Ki-67 nuclei 
nuclei localized beneath the line of Auber in the matrix. In the outer root sheath, 
(arrows). Positive nuclei can likewise be seen positive nuclei can be seen in the outer root 
in the outer root sheath (arrow-head). sheath (arrows) (Original magnification: χ 
63). 
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Fig. 5. Transverse section of two telogen germinal units, containing no positive Ki-67 nuclei 
(original magnification: χ 63). 
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DISCUSSION 
The monoclonal antibody Ki-67 reacts with nuclei of actively cycling cells in the 
proliferating phase (G,, S, G2, M) of the cell cycle4. We used the immunohistoche-
mical assessment of Кі-67-binding to determine the number of cycling cells in 
anagen hairs of alopecia areata as compared to normal scalp skin. 
The presence of Кі-67-positive nuclei was most pronounced in the area below 
the critical line of Auber and the exterior part of the outer root sheath. Notably, 
positive nuclei of the outer root sheath were located in the outermost part, indicating 
that relatively rapid cell proliferation is also an essential part of the outer root sheath 
of the anagen hair follicle8. It is known from autoradiography, that the cells of the 
outer root sheath include DNA-synthesizing cells3. This study shows that also in hair 
follicles, there is an association between the expression of Ki-67 antigen and cell 
proliferation. 
Recently Ki-67 was studied in human axillary hairs9. The authors found 
nuclear staining in a small number of matrix cells and in some outer root sheath 
cells. They found two different patterns of cytoplasmatic staining in the outer root 
sheath: an intense staining of the innermost cells and a weaker staining of the outer 
root sheath cells in the isthmus. In scalp hair follicles no cytoplasmatic staining of 
Ki-67 was found. Whether this discrepancy is dependent on differences in 
localization remains to be investigated. 
Interestingly, the number of Кі-67-positive nuclei at level 1 in alopecia areata 
showed a significant decrease when compared with the corresponding level in 
normal skin. This tallies with earlier studies10 which showed by direct counting a 
proportionate reduction of mitotic cells in the matrix. It is known that in alopecia 
areata the hair bulbs are blocked in anagen stage IV" and that the DNA-synthesis is 
restrained12. We therefore can conclude that Ki-67 reactivity is correlated with 
findings on DNA-labelling as reported in the literature. 
The present study demonstrates that an immunohistochemical method using 
the monoclonal Ki-67, which binds to nuclei of cells in the proliferative phases of 
the cell cycle, is a useful tool when studying the number of proliferative cells in hair 
follicles. These findings confirm the results obtained previously by labelling with 
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thymidine and bromodeoxyundine The decrease of nuclear Ki-67-binding observed 
in alopecia areata suggests that abnormal growth of cells in the hair bulbs is of 
pathogenetic significance 
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SUMMARY 
Alopecia areata is a human hair disease of unknown etiology. Immunological 
mechanisms, alterations in the extracellular matrix, and follicular growth 
abnormalities have been suggested as a possible cause. Here we compare the 
expression of cytokeratins in normal hair follicles to that of alopecia areata using 
immunohistology with monoclonal antibodies. A number of cytokeratins were 
specifically expressed in defined anatomical parts of the follicle; however, no gross 
qualitative or quantitative differences were found between normal and diseased scalp. 
Interestingly, the expression of cytokeratin 16, which is modulated by conditions that 
affect the rate of keratinocyte proliferation, was found to be unchanged in the outer 
root sheet of alopecia areata follicles. This is in contrast with earlier observations of 
a decrease in the expression of the proliferation-associated, Ki-67 nuclear antigen. 
INTRODUCTION 
A number of mechanisms have been suggested to underlie the common hair disease 
alopecia areata. Immunological abnormalities, including autoantibody formation1 and 
aberrant expression of HLA class II antigens have been found23. It is, however, not 
clear whether these factors are causal or consequential. The finding that topical 
immunotherapy is successful in the treatment of alopecia areata lends further support 
to an immune-mediated process4 5. Other mechanisms studied in alopecia areata 
include the expression of extracellular matrix proteins6 7 and follicular growth 
abnormalities8 ' . 
In this study we have investigated whether a disturbance of the differentiation 
process in hair follicle keratinocytes is associated with the pathologic changes seen 
in alopecia areata. As cytokeratins represent the most abundant proteins in the hair 
follicle and are generally accepted markers for the type and stage of epithelial 
differentiation10 these constituents can serve as key molecular markers for differen-
tiation events in the hair follicle. We therefore investigated whether the cytokeratin 
pattern in alopecia areata is altered, either due to an intrinsic abnormality or as a 
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consequence of the inflammatory process. 
MATERIAL AND METHODS 
Biopsies 
Excisional scalp biopsies were taken from 5 healthy controls and from the margins 
of active lesions of 5 patients suffering from alopecia areata. All biopsies were 
immediately embedded in Tissue-Tek II Compound (Miles Inc., Diagnostics 
Division, Elkhart, Ind., USA), snap-frozen in liquid nitrogen and stored at -80CC 
until further use. Sections (5 μιη) were cut using a 2800 Frigocut-N cryostat 
(Reichert-Jung, Cambridge Instruments GmbH, Nußloch, Germany) at -28°C". The 
sections were placed on bovine serum albumin-coated slides, air-dried for at least 30 
min and then fixed with acetone for 10 min and stored in sealed boxes at -80°C until 
use. 
Immunohistochemistry 
Detailed information of the antibodies used for immunohistochemical staining is 
given in Table I. The immunoperoxidase staining procedure was performed as 
follows. The acetone-fixed sections were rehydrated with phosphate-buffered saline 
(PBS) containing 0.01% Tween 80 for 3 min, then incubated in a humidified 
chamber at room temperature for 30 min with the primary antisera diluted in PBS. 
After washing in PBS, sections were incubated with peroxidase conjugated rabbit 
anti-mouse immunoglobulins (Dakopatts, Glostrup, Denmark) in a dilution 1:50 in 
PBS with 5% normal human AB- serum for 30 min at room temperature. After 
washing with PBS, the sections were preincubated with sodium acetate buffer (pH = 
4,9) and finally stained in sodium acetate buffer containing 200 mg/1 3-amino-9-
ethylcarbazole solution (Sigma Chemical Company, St Louis, Mo., USA) and 
0.01% H202 (prepared freshly) for 10 min at room temperature in the dark. After 
two washes with demineralized water the sections were counterstained with Mayer's 
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haematoxylin solution (Sigma) and mounted in glycerin-gelatin. The sections were 
examined using a Zeiss photomicroscope. 
Table I. Monoclonal antibodies used in this study 
MoAb Cytokeratin 
specificity 
Source/References 
RCK 102 
M20 
RKSE60 
2D7 
КД12 
K14/CKB1 
E3 
M9 
Cytokeratin 5,8 
Cytokeratin 8 
Cytokeratin 10 
Cytokeratin 13 
Cytokeratin 13, 16 
Cytokeratin 14 
Cytokeratin 17 
Cytokeratin 18 
LP2K/RPN-1165 Cytokeratin 19 
Euro-Diagnostics BV (Apeldoorn, The 
Netherlands)12 
G.N.P. van Muijen13 
Euro-Diagnostics BV (Apeldoorn, The 
Netherlands)14 
Euro-Diagnostics BV (Apeldoorn, The 
Netherlands) 
Sigma, St. Louis, USA 
Sigma, St. Louis, USA 
S.M. Trojanovsky (Moscow, Russia)" 
G.N.P. van Muijen16 
Amersham International PLC, Aylesbury, 
Buckinghamshire, UK17 
RESULTS 
Anagen and telogen hair follicles were studied in biopsies from alopecia areata pa­
tients and from normal control subjects in horizontal and vertical sections. The 
descriptions of the follicular cytokeratin expression patterns apply to anagen of both 
normal and diseased scalp. The observations are summarized in Fig. 1. 
The monoclonal antibody (MoAb) RCK102, directed against cytokeratins 5 
and 8 showed staining restricted to the outer root sheath (ORS) (Fig. 2) and the 
centre of the medulla of the hair (Fig. 3). When the ORS reached the level of the 
infundibulum only the basal layer showed a positive staining, which continued in the 
basal layer of the epidermis. In the telogen germinal unit, the centre showed a 
positive staining. 
A quite different pattern was found with MoAb M20, which is a cytokeratin 
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8 specific antibody. M20 reactivity was found focally in the ORS showing positive 
cells in the innermost part of the ORS (Figs. 4,5). Also the cortex of the hair was 
stained (Fig. 5). 
Expression of cytokeratin 10 (Moab RKSE60) was limited to the suprabasal 
cells of the ORS, which showed positivity at the level of the drainage of the 
sebaceous glands and extended to the epidermis, where it continued as a suprabasal 
staining pattern (not shown). 
Cytokeratin 13 (MoAb 2D7) showed a positive staining at the dermal level in 
the most exterior part of the ORS (Fig. 6), which was absent at the epidermal level 
(not shown) and also in the outer cell layer of the hair cutícula (Fig 7). 
Fig. 1. Schematic representation of the expression of cytokeratins in an anagen hair follicle. 
UORS, upper outer root sheath; LORS, lower outer root sheath; 1RS, inner root sheath; DP, 
dermal papilla; SB, suprabasal; В, basal. 
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Ks8.12, which has specificity for the cytokeratins 13 and 16 (and possible 
14), showed a positive staining of the not yet differentiated ORS (not shown). At the 
dermal level, the ORS showed a positive staining of the most exterior part, which 
continued in the epidermis as a positive basal cell layer (Fig. 8). When a complete 
hair, composed of medulla, cortex and cutícula had developed, the layer of Huxley 
showed some staining, and the layer of Henle was invariably stained. 
Cytokeratin 14 (MoAb K14) was expressed in the medulla above the top of 
the dermal papilla, although less pronounced as compared to the ORS (Fig. 9). 
Figure 10 shows cytokeratin 14 expression in the ORS of an anagen hair follicle, 
with a minor staining of the matrix at the top of the dermal papilla. At the bulbar 
level the ORS was constituted of one cell layer of positive cells; upwards the number 
of cell layers in the ORS increased and the total ORS remained positive. At the 
epidermal level, cytokeratin 14 expression was only found in the basal layer (not 
shown). 
Cytokeratin 17 (MoAb E3) showed weak staining of the ORS with exception 
of the basal part (Fig. 11). In horizontal sectioning the medulla and cortex 
occasionally showed a positive staining. 
Fig. 2. Immunoperoxidase staining reaction 
of an anagen hair follicle from normal scalp 
cross-sectioned at the papilla level. Note the 
pronounced staining of the ORS with MoAb 
RCK102. 
Fig. 3. Immunoperoxidase staining reaction 
of an anagen hair follicle from normal scalp 
with MoAb RCK102, showing a positive 
staining of the centre of the medulla. 
4 . 
'"4 
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Fig. 4. Immunoperoxidase staining reaction 
of a vertically sectioned hair follicle from 
normal scalp, showing the positive cluste­
ring (arrows) representing cytokeratin 8, as 
detected by M20. 
Fig. 5. Expression of cytokeratin 8 in a hair 
follicle from normal scalp, horizontally 
sectioned and showing the positive cortex 
and the positive clustered cells in the 
innermost part of the ORS. 
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Fig. 6. Immunoperoxidase staining reaction 
of a hair follicle from normal scalp, sho­
wing cytokeratin 13 (MoAb 2D7) expression 
in the basal part of the ORS. 
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Fig. 7. Immunoperoxidase staining reaction of 
an anagen hair follicle from normal scalp at the 
level of the dermal papilla, showing 
cytokeratin 13 expression (MoAb 2D7) in the 
outerpart of the ORS and also in the hair 
cutícula. 
Fig. 8. Immunoperoxidase staining of alopecia 
areata scalp, showing a positive staining with 
Ks8.12 of the most exterior part (basal), which 
continues in the epidermis (not shown) as the 
basal layer. 
Fig. 9. Hair follicles of an alopecia areata 
patient, showing diminished CK 14 staining in 
the centre of the medulla as compared to the 
ORS. 
' 4я ? i 
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Fig. 10. Vertically sectioned anagen hair 
follicle in normal scalp with a positive cyto-
keratin 14 staining of the ORS with hardly any 
staining of the top of the dermal papilla 
(arrow). At the hair bulb level only a single 
positive cell layer is shown, which becomes 
positive in all the layers in the distal direction. 
Fig. 11. Cross sectioning of a hair follicle 
from normal scalp with mild cytokeratin 17 
(MoAb E3) staining of the ORS with exception 
of the basal cell layer. (Original magnification 
x200) 
Cytokeratin 18 expression (MoAb M9) in the ORS was found sporadically, in 
the most internal part, showing some scarce positive cell groups (not shown). 
Cytokeratin 19 (MoAb LP2K) was not consistently expressed in the lower 
part of the ORS, consisting of only one cell layer. When the ORS is multi-layered, 
positive cell clustering can be seen, which disappears at the level of the papillary 
dermis (not shown). 
Catagen and telogen hairs are structurally different from anagen hair follicles 
in that most of the structures and cell layers, that characterize anagen hair follicles, 
like the matrix, inner and outer root sheath and the hair cutícula, are lacking. When 
we examine the cytokeratin expression in catagen and telogen hairs, it is found for 
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Moab RCK102 and Ks8.12 that the whole centre of the telogen germinal unit is 
strongly positive, this in contrast with anagen hair follicles in which RCK102 and 
K,8.12 staining is restricted to the ORS. The other MoAbs tested showed similar 
staining patterns, depending on the level in the dermis. 
In alopecia areata, the biopsies examined were from margins of active 
lesions, so-called, the acute progressive phase, characterized by infiltrates around the 
growing anagen hair follicles and different grades of hair matrix destruction. The 
heavily infiltrated follicles showed a disturbance of the follicular architecture. 
However, the cytokeratin expression pattern in the hair follicles of alopecia areata 
compared with normal scalp showed no gross differences. 
DISCUSSION 
Expression of cytokeratins in normal human hair follicles has been documented by 
several authors, using either biochemical or immunohistochemical methods. It was 
shown by 2-dimensional gel electrophoresis that keratins 5, 6, 14, 16 and 17 were 
expressed in the ORS10 and keratins 1 and 10 in the inner root sheath and cuticle18. 
Some of these cytokeratins could be located at specific anatomical sites within the 
hair follicle by means of immunohistochemistry1921, indicating that also in the hair 
follicle, cytokeratins can be used as tissue- and differentiation-specific markers. 
Here we present a detailed study, using a panel of 9 monoclonal antibodies 
(most of them monospecific) showing the spatial distribution of a number of 
cytokeratins in follicles of normal scalp. The findings were compared with scalp 
tissue from alopecia areata patients. Although not all Moabs were monospecific, and 
the specificity of some of them needs further characterization, most of the antibodies 
used are informative markers for follicular compartments. It has to be noted that the 
cytokeratins studied here do not include hair-specific "hard" keratins. As shown by 
others19"21 and also in this study, cytokeratins typical for basal cells (CK 5, 14 and 
17), hyperproliferative keratinocytes (CK 16), suprabasal differentiated keratinocytes 
(CK 10), and simple epithelia (CK 18 and 19) can be found in hair follicles. 
It has been shown in several studies that alterations in the expression of 
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cytokeratins can be found in certain diseases22"**. Disturbance of intermediate 
filament formation due to mutation of the CK 14 gene was shown to contribute to 
the cause of epidermolysis bullosa simplex25. In other diseases (e.g. psoriasis), 
cytokeratin 16, which is not normally expressed suprabasally in epidermis can be 
found in the suprabasal compartment of the hyperproliferative epidermis26 27. In 
addition the expression of CK 10 was found to be diminished28. Here, we compared 
the cytokeratin expression pattern of alopecia areata with that of normal scalp, in 
order to investigate abnormalities in follicular differentiation. As we have shown 
before that alopecia areata hair follicles show a decrease in the expression of the 
nuclear proliferation-associated Ki-67 antigen9, we anticipated a possible down-
regulation of the expression of the hyperproliferation-associated cytokeratin, 
concomitantly with effects on CK 10 expression i.e. the reverse effect of what is 
found in psoriatic conditions. However, as shown above, no gross quantitative or 
qualitative differences were found. Whether this means that expression of CK 16 and 
a hyperproliferative status of the tissue are not coupled per se, or that the decrease 
of follicular growth rate in alopecia areata is too marginal to exert a measurable 
effect histologically, is not clear. It was recently shown that keratin 16 antibody 
LL025 in squamous cell cacinoma of the human lung, stains more cells with 
increasing degree of differentiation, suggesting that keratin 16 is a marker for 
(abnormal) squamous differentiation rather than for a hyperproliferative state2'. 
Future studies will be directed towards the expression of hair-specific keratins in 
alopecia areata and are needed for further investigation of aberrant differentiation 
processes in this disease. 
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SUMMARY 
One hundred thirty-nine patients with severe alopecia areata (the majority with the 
subtotal, total or universalis type) were treated with topical immunotherapy 
(diphenylcyclopropenone). Patients were initially treated unilaterally; the other side 
of the scalp served as a control. In 50.4% of the patients the response was either 
excellent (total regrowth) or satisfactory (subtotal regrowth with only a few 
remaining bald patches). The most frequent side effects were eczematous reactions 
with blistering, spreading of the induced contact eczema, and sleep disturbances. 
INTRODUCTION 
In studies of topical immunotherapy for alopecia areata (AA), the results have varied 
widely1"12. Most reports deal with small groups of patients. The purpose of this study 
is to analyze the effectiveness and possible side effects of this mode of treatment in a 
large group of patients. 
Toxicological data have established a preference for diphenylcyclopropenone 
(diphencyprone, [DCP]) rather than dinitrochlorobenzene, the first contact allergen 
used in the treatment of AA. DCP is not mutagenic in the Ames test13 and 
teratogenicity and organ toxicity could not be detected in the hen's egg test or in the 
mouse teratogenicity assay1415. 
DCP is stable for at least 4 weeks if shielded from light16 but it is our 
impression that the stable shelf life of the drug is at least 6 months and probably 
longer. In general, fresh solutions have been prepared every 6 months. 
PATIENTS AND METHODS 
One hundred thirty-nine patients with severe AA (the majority of the subtotal, total 
or universalis type) were treated with DCP between March 1986 and October 1989, 
according to a standard protocol17. All patient gave their informed consent. 
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The DCP we used (Janssen Chimica, Beerse, Belgium) was 98% pure. To 
assure additional safety, we performed the following repurification procedure twice: 
500 ml of cyclohexane was added to 10 gm of DCP and heated until DCP dissolved. 
The solution was crystallized at room temperature. DCP was then dissolved in 
acetone and stored in dark vials. Sensitization was performed with a 2.0% solution 
of DCP; approximately 50 cm2 of the scalp was firmly rubbed during 20 seconds. 
Elicitation was done by application of two consecutive swabs to one side of the scalp 
at weekly intervals, starting in general with a concentration of 0.001%. If a mild 
contact eczema was not obtained, the DCP concentration was increased stepwise. 
DCP concentrations used were 0.0000001/ 0.000001/ 0.00001/ 0.0001/ 0.001/ 0.01/ 
0.05/ 0.1/ 0.5/ 1.0/ 2.0%. In most cases the DCP concentration had to be changed 
during treatment by one or two steps. 
One side of the scalp was treated weekly until hair growth appeared. If hair 
growth was significantly better on the treated side, treatment of the entire scalp was 
started; if hair growth appeared to the same degree on both sides under unilateral 
therapy, treatment was stopped because this was considered as a spontaneous 
remission. A unilateral response is mostly seen within 6 months of uninterrupted 
treatment and only exceptionally occurs later14 IB. In this study patients were advised 
not to stop treatment until they had a continuous therapeutic reaction for at least 7 
months. 
The following laboratory tests were performed at least every 3 months: RBC, 
WBC, platelet counts, transaminase ,γ-glutamyl transferase, alkaline phosphatase, 
urea, and creatinine levels. 
RESULTS 
Type of AA at the start of DCP treatment. The type of A A was documented 
before treatment (Table I). "Subtotal" means hair loss of more than 90%. 
Results of DCP treatment for AA. The results of DCP treatment are shown in 
Table II. The chance of an excellent (total regrowth) or satisfactory (subtotal 
regrowth) response was 50.4% (70 of 139 patients) for the entire group and 65.4% 
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(70 of 107) for those patients who initially had shown a unilateral response. Fig. 1 
shows a patient with an excellent response. 
Satisfactory treatment results. Patient satisfaction with subtotal regrowth and 
possible discrepancies in appreciation between patients and physicians were 
investigated. 
Fig. 1. Results of topical immunotherapy for alopecia areata with DCP: A, Before 
treatment. B, after 20 weeks of unilateral treatment. C, After 8 weeks of bilateral 
treatment. D, After 58 weeks of bilateral treatment. 
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Twenty of 28 patients with a response regarded by the physician to be satisfactory 
(Table II) were asked to give scores between 0 (for a result considered as failure) 
and 10 (for a result regarded as excellent). At the same time the physician was asked 
to do the same. The average score of the patients was 7.7 whereas the physician 
score averaged 7.4 with a maximum patient-physician discrepancy of 2 points. 
Unilateral response. Fig. 2 shows the number of applications including 
sensitization needed for an unilateral response in the group of 107 patients who 
showed this effect; the average is 14. Fig. 3 shows the number of applications 
needed for a unilateral response, calculated from the first successful elicitation; the 
average number of applications is 11 (the assumption is made that hair regrowth can 
only take place if a sufficient contact eczema is achieved and maintained). 
Table I. Type of alopecia areata (AA) as documented before DCP treatment 
Type of AA 
Patchy 
Subtotal 
Total 
Subtotal/universalis 
Total/universalis 
Diffuse 
Diffuse/patchy 
Ophiasis 
Ophiasis/patchy 
No. of patients 
(JV = 139) 
44(31.7%) 
24(17.3%) 
15 (10.8%) 
17 (12.2%) 
29 (20.9%) 
4 (2.9%) 
1 (0.7%) 
3 (2.2%) 
2 (1.4%) 
Therapy resistant relapse, "tolerance " phenomenon and "castling ". Thirty of 
107 patients who had a unilateral response relapsed during treatment of the entire 
scalp were resistant to further therapy. Eight of these patients had already had 
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subtotal regrowth and an additional four patients had experienced total regrowth. In 
eight of these patients who had initially responded well a "tolerance" phenomenon 
was seen, defined as a continuous increase in DCP concentration until a 
concentration of 2.0% was reached without producing an adequate dermatitis, 
resulting in the loss of all regrown hair. In three patients the puzzling phenomenon 
of "castling", a paradoxical growth of hair at the untreated side of the scalp5· was 
documented. 
Table II. Results obtained with DCP treatment in alopecia areata 
No. of patients 139 
Unilateral response 107 (77.0%) 
Total regrowth after subsequent bilateral 42 (30.2%) 
treatment 
Subtotal regrowth after subsequent bilateral treat- 28 (20.1 %) 
ment 
Side effects of DCP treatment. A mild degree of eczema appeared to be 
sufficient to induce hair regrowth. An eczematous reaction of increased severity with 
blistering was observed in 81 patients and occurred only once during treatment. This 
was due to an unpredictable change in the response to DCP. In general, interrupting 
elicitation for 1 or 2 weeks followed by the use of a lower DCP concentration was 
sufficient and no additional treatment was needed. Forty-eight of 131 patients 
interviewed had sleep disturbances because of itching, mostly during the night after 
elicitation. Spreading of contact eczema to the neck and the face was observed in 
four patients and to the rest of the body in seven patients. Urticaria was seen in 
seven patients. Swelling of the scalp was seen in one patient and edema of eyelids or 
other parts of the face was observed in five patients. An erythema multiforme-like 
eruption occurred in 2 patients". Three patients had frequent headaches. Swelling of 
lymph nodes, especially in the neck and behind the ears, occurred in virtually all 
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patients. 
Laboratory tests. Computer analysis of laboratory results revealed no 
significant abnormalities. 
number of patients (n=107) 
Fig. 2. Number of DCP applications, including sensitization, to obtain a unilateral response 
in terms of hair growth. 
number of patients (n=107) 
number of applications 
Fig. 3. Number of DCP applications that are necessary, after the first successful elicitation, 
to obtain a unilateral response in terms of hair growth. 
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DISCUSSION 
Treatment with DCP was effective m this large group in which patients with severe 
AA are over-represented The response rate may have been higher than 50 4% in an 
unselected group of patients 
The mean number of applications needed after sensitization to get the first 
eczematous reaction was three More than 30 weeks after the first successful 
ehcitation, two patients had a unilateral response but only one had a satisfactory 
response afterwards An uninterrupted treatment period of 30 weeks after the first 
successful ehcitation can therefore be regarded as a safe limit for stopping DCP 
treatment because later on a good response is unlikely Although the chance of 
maintaining a satisfactory or excellent response is high (85 4%), a therapy resistant 
relapse may occur Disappearance of reactivity to the contact allergen ("tolerance" 
phenomenon) occurred in eight patients (5 8%) In contrast with other authors20"23, 
we were not able to reverse this with Cimetidine 
Itchmg, often causing sleep disturbances during the mght after ehcitation, and 
swelling of lymph nodes are side effects that are required for a therapeutic response 
An eczematous reaction with blistering was common but mostly occurred only once 
m the same patient Spreading of the induced contact eczema is possible Regular 
laboratory tests did not show any abnormality Nevertheless, we do not regard this 
mode of treatment as suitable for routine use 
Although hair growth often remains unaffected by gradual discontinuation of 
DCP treatment, renewed activity of AA is possible 
When hair loss recurs after discontinuation of DCP treatment, there is a good chance 
of response to resumed treatment 
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SUMMARY 
One hundred thirty-nine patients with alopecia areata were treated with 
diphenylcyclopropenone. Before treatment, 85 patients had subtotal or total hair loss 
(>90% bald area) and in the remaining patients scalp involvement was between 
40% and 90%. The following three factors were found to be of prognostic 
significance: type of alopecia areata as documented before treatment, duration of the 
disease before therapy and presence of nail changes. Other factors such as age of 
onset, sex, presence of atopic features, the extent of variation in the range of 
diphenylcyclopropenone concentrations during treatment, and sleep disturbances 
caused by pruritus did not influence the prognosis significantly. 
INTRODUCTION 
Because topical immunotherapy for alopecia areata (AA) is a time-consuming 
method, it would be desirable to know prognostic factors that influence the response 
as a basis for possible selection. In reports on topical immunotherapy for AA, 
prognostic significance has been attributed to various factors: type of AA17, duration 
before treatment1·46·8"11, presence of nail changes12, age at onset12·13, sex5, and 
atopy91012. 
The aim of the present study was to evaluate the influence of these factors on 
the response of 139 patients with AA to treatment with diphenylcyclopropenone 
(DCP). In addition, the possible prognostic influence of two factors that so far have 
not been mentioned in the literature was investigated: the extent of variation in the 
range of concentrations of the contact allergen during treatment and sleep 
disturbances caused to pruritus. 
PATIENTS AND METHODS 
One hundred thirty-nine patients with severe AA were treated with the contact 
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allergen DCP according to a standard protocol14. The type of AA was classified as 
follows: "patchy" (40 to 90% loss of scalp hair: 44 patients), "subtotal" (90 to 99% 
loss of scalp hair: 24 patients), "total" (loss of all scalp hair: 15 patients), "subtotal-
universalis" (loss of all scalp hair with some body hair left: 17 patients), "total-
universalis" (loss of all scalp and body hair: 29 patients), "diffuse-type" (40 to 90% 
diffuse loss of scalp hair: 5 patients) and "ophiasis-type" (40 to 90% loss of scalp 
hair in the temple and occiput areas: 5 patients). Loss of less than 40% was not 
treated. A patient was considered to have nail changes if the nails showed one or 
more of the following features: pitting, sandpaper nails, transverse folds, 
leukonychia punctata, brittleness, "red spotted lunula" and onychomadesis. With the 
exception of eight cases, patients were asked whether they had experienced atopic 
manifestations in the form of asthma, atopic eczema or hay fever. No 
subclassification of these atopic features was made. DCP concentrations were 
defined as "stable" if they remained within a range of three consecutive 
concentrations (0.0000001/ 0.000001/ 0.00001/ 0.0001/ 0.001/ 0.01/ 0.05/ 0.1/ 0.5/ 
1.0/ 2.0%)14. With the exception of eight cases, patients were asked for sleep 
disturbances. These were registered as present if sleep had been disturbed because of 
pruritus after at least three elicitations. 
RESULTS 
Table I shows possible prognostic factors that have been investigated. For evaluation 
of the influence on prognosis, classifications of individual factors were made as 
shown under "category". Response rates for the various categories are also given. 
Fig. 1 shows the duration of AA before DCP treatment. The age at onset of AA is 
shown in Fig. 2. In two cases, duration of untreated AA and age of onset were 
unknown. The rate of satisfactory responses, defined as the percentage of patients 
with subtotal or total regrowth, was 50.4% (70 of 139 patients)14. To evaluate the 
importance of each significant factor, correlations between these three factors were 
investigated. A significant correlation between the type of AA at the beginning of 
DCP treatment and the duration of untreated AA was found (chi-square-test: ρ < 
82 Chapter 6.2 
0.03). There was also a significant correlation between the type of AA at the start of 
DCP treatment, with the exception of ophiasis and diffuse types (both were rarely 
included: 10 of 139 or 7.2%), and the presence of nail changes (chi-square test: ρ 
< 0.02); when ophiasis and diffuse types are included, the tendency is obvious (chi-
square test: ρ = 0.06). 
Table I. Evaluated factors of possible prognostic significance in DCP treatment of alopecia 
areata (AA). 
Factor Category Response rate ρ Value 
Type of AA 
Duration of untreated AA (yr) 
Nail changes 
Age of onset (yr) 
Sex 
Atopic features 
DCP variation 
Sleep disturbances 
Patchy 
ST/T/ST-U/T-U 
Diffuse/ophiasis 
Up to 1 
2-9 
10-39 
None 
> 1 
2-19 
20-34 
35-69 
Male 
Female 
None 
Ξ> 1 
"Stable" 
"Unstable" 
Present 
Absent 
77.3% (34/44) 
38.8% (33/85) 
30.0% (3/10) 
63.9% (23/36) 
53.6% (30/54) 
36.2% (17/47) 
62.3% (38/61) 
41.0% (32/78) 
42.9% (24/56) 
55.6% (25/45) 
58.3% (21/36) 
50.0% (33/66) 
50.7% (37/73) 
54.3% (44/81) 
50.0% (25/50) 
55.4% (51/92) 
40.4% (19/47) 
54.2% (26/48) 
51.8% (48/83) 
<0.0001 
<0.03 
<0.01 
n.s. 
n.s. 
0.09 
n.s., No statistical significance; ST/T/ST-U/T-U, 
universalis. 
subtotal/total/subtotal-universalis/total-
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A significant correlation between the duration of hair loss and nail changes was not 
found (chi-square test: ρ = 0.37). Further analysis showed that subtotal/ total/ 
subtotal-universalis/ total-universalis AA is correlated with a longer duration of AA 
and the presence of nail changes, both being unfavorable prognostic factors by 
themselves. 
As the different prognostic factors are interrelated, multivariate analysis was 
used to test their influence on the response to find possible cross effects. Logistic 
regression of the response with the three factors still reveals significance with a 
ranking comparable to the univariate analysis (Table II). The likelihood ratio 
indicates that these three factors are enough to fit the data. 
number of patients (n=137) 
10-14 20-24 30-34 40-44 
age of onset (years) 
Fig. 1. Age at onset of alopecia areata. The shaded part of each bar indicates number of 
patients with subtotal or total regrowth. 
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number of patients (n=137) 
12-13 16-17 20-21 24-25 26-29 32-33 36-37 4041 
duration of untreated AA (years) 
Fig.2. Duration of AA before DCP therapy. The shaded part of each bar indicates number 
of patients with subtotal or total regrowth. 
Table II. Multivariate analysis of prognostic factors in DCP treatment of AA. 
Prognostic factor ρ Value 
Type of AA 
Duration of AA 
Nail changes 
Likelihood ratio 
0.002 
0.03 
0.02 
0.21 
DISCUSSION 
Our results show that the type of AA present at the beginning of topical 
immunotherapy is the major prognostic factor. 
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The degree of scalp involvement is inversely correlated with prognosis. This is in 
agreement with our previous findings1"3·6 and with those of other investigators4 5 7, 
although at variance with some other reports1516. 
The duration of A A before treatment was found to be a second, independent 
prognostic factor. This is in accordance with most previous reports4'6'8"'1 but contrary 
to others7 1 5 1 6. (In this respect our own preliminary views have been contradictory1-3) 
The presence of nail changes can be considered a third independent 
prognostic factor. An unfavorable influence of nail changes on prognosis has been 
found previously12. 
The differences in response rate according to the age at onset categories were 
not significant. This is in contrast with other reports12 n . Response rates of men and 
women were the same. This is at variance with the results of one study5. Contrary to 
other reports on the negative prognostic influence of atopy91012, the presence of one 
or more atopic features did not influence the response. 
The DCP concentration generally varies to some degree during treatment17. 
Major variations, however, may reflect difficulties in the continuous maintenance of 
a mild contact eczema, a prerequisite for the therapeutic response. Conversely, an 
adequate response to a small range of DCP concentrations might be a favorable 
prognostic sign. Differences in response rate between "stable" and "unstable" DCP 
concentrations were not significant, although a tendency towards significance was 
present (chi-square test: ρ = 0.09), Presence of sleep disturbances because of 
pruritus is a measure, albeit subjective, of the severity of contact eczema, which 
might be indicative of a therapeutic response, as suggested by previous reports1013 " . 
No influence on prognosis was found and this is in accordance with another study19. 
In everyday practice, the question most often raised by patients is the 
probability of response to treatment. The main factor is the extent of hair loss. Our 
data indicate that scalp involvement of 40 to 90% has a response rate of 
approximately 75%; for more extensive hair loss the response rate is approximately 
40%. These rates are further influenced by the duration of untreated AA and by the 
presence of nail changes: both a long duration of A A before therapy and nail 
involvement have a negative influence on the chance of response. 
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SUMMARY 
Twenty-seven patients with severe alopecia areata were treated with dapsone. The 
results of a mean treatment duration of 10 ± 0.5 months, are reported and compared 
with the results of long-term topical immunotherapy obtained previously at the same 
institute. The efficacy of dapsone proved to be markedly inferior to the efficacy of 
topical immunotherapy. The percentage of patients showing regrowth of hair during 
treatment with dapsone was comparable with the occurrence of spontaneous regrowth 
of hair as reported in literature. 
INTRODUCTION 
Alopecia areata is a hair disease of unknown etiology, though evidence for an auto-
immune etiology continues to mount1. Various therapies have been reported to be 
successful: photochemotherapy2, topical and systemic corticosteroids3 4, topical and 
oral cyclosporin A5 6, topical and oral minoxidil7 * and Inosiplex*. None of these 
treatments, however, yielded a substantial regrowth of hair in the majority of 
patients. During the last decade controlled studies have shown conclusively that the 
treatment of alopecia areata with topical immunotherapy using the contact allergen 
diphenylcyclopropenone (DCP) is an effective treatment10 n . A disadvantage of 
topical immunotherapy is that this approach requires intensified supervision and that 
the treatment is demanding for the patient. Therefore it remains worthwhile to 
search for new treatments for patients with alopecia areata. 
In 1990 Knauber and Zaun12 stated that the treatment of alopecia areata with 
dapsone is as effective as the topical immunotherapy. However, so far no consensus 
has been reached on the value of dapsone for patients with alopecia areata13. The 
purpose of this study is to analyze the effectiveness of dapsone in alopecia areata and 
to compare the results with the response to topical immunotherapy obtained at the 
Nijmegen Institute1014. 
Dapsone versus topical immunotherapy in alopecia areata 91 
PATIENTS AND METHODS 
Between January 1992 and August 1993 twenty-seven patients with severe alopecia 
areata were treated with dapsone. Between March 1986 and October 1989, a group 
of 139 patients with severe alopecia areata have been treated with DCP at the 
Nijmegen Institute10. Informed consent had been obtained from all patients. 
Included in both groups were those patients suffering from severe alopecia areata. 
Excluded were pregnant women and those wishing to become pregnant. Patients with 
cardiopulmonary disease were excluded from treatment with dapsone. Table I 
summarizes the composition of the group of patients treated with dapsone and the 
group of patients treated with DCP. Eleven patients included for dapsone treatment, 
had been treated previously with topical immunotherapy. In 8 of these patients, 
topical immunotherapy had been initially successful, but a relapse had occurred 
during prolonged immunotherapy. 
Table I. Composition of study populations 
Treatment 
Dapsone 
DCP10 '4 
Number 
of 
patients 
27 
139 
Sex 
(M/F) 
15/12 
66/73 
Duration 
of AA 
(years) 
<1 :2(7%) 
2-9 : 15 (56%) 
10-39: 10(37%) 
< 1 : 36 (26%) 
2-9 : 54 (39%) 
10-39 : 47 (34%) 
Type of AA 
Patchy : 7 
ST/T/ST-U/U : 20 
Patchy : 44 
ST/T/ST-U/U : 85 
diffuse/ophiasis :10 
ST/T/ST-U/U = subtotal/total/subtotal-universalis/universalis 
The details of patients treated with DCP have been reported previously10 M. 
Dapsone was started at a daily dosage of 100 mg. In case of adverse effects like 
nausea, headache, sleep disturbances, anaemia or methaemoglobinaemia, the dosage 
was reduced to 50 mg daily or even stopped. This dosage was continued until 
cosmetically acceptable hair growth had appeared. Then the dosage was reduced 
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slowly to the minimally effective dose. If after 12 months no hair growth had 
appeared, the therapy was stopped. Before treatment, we checked complete blood 
count with differential white blood count, renal and hepatic function tests. During 
treatment complete blood count, methaemoglobin, renal and hepatic functions were 
monitored. 
Topical immunotherapy was carried out according to standardized procedures1014. 
Hair regrowth was recorded. If some regrowth of hair was recorded the response 
was designated as "hair growth" and if the regrowth was complete and totally satis-
factorily, the response was recorded as "complete hair regrowth". 
RESULTS 
Data on hair growth during the treatment with dapsone are summarized in Tables II, 
III and IV. Out of these patients with the patchy type 4 patients showed full 
recovery. Fourteen patients of the total group of patients treated with dapsone, 
showed a sporadic hair growth on the scalp. Out of these 14 patients, 8 patients 
noticed a sparsely hair growth all over the body, that disappeared later. In the 
totalis/universalis group 10 patients showed some hair growth but only in 2 patients 
complete hair growth occurred. In these 2 patients the hair growth appeared after 1 
and 5 months, and the therapy was stopped at 10 and 8 months because of headache 
and fatigue. Remarkably, the hair growth proved to be unaffected by discontinuation 
of dapsone. 
Table IV summarizes the duration of the treatment phases. It can be seen that 
first improvement during dapsone therapy was seen after 2.2 ± 0.6 months in 14 
patients and that cosmetically acceptable regrowth was seen after 10 ± 0.7 months 
in 6 patients. The dose of dapsone decreased during treatment due to side effects. 
No significant correlation was observed between the dosage of dapsone and the 
clinical efficacy. Notably, the patients in the totalis/universalis group, who showed 
successful hair growth received dapsone 50 mg a day. 
Topical immunotherapy with DCP was continued for one year in 139 
patients1014. After this year the therapy for patients without a cosmetically acceptable 
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hair growth was discontinued. Data on hair regrowth during immunotherapy are 
presented in Tables III and IV. Out of the 44 patients with the patchy type of 
alopecia areata, 34 had complete hair regrowth and out of the 85 patients with 
subtotalis/totalis type of alopecia areata 33 had complete hair regrowth. As topical 
immunotherapy is initiated at one side of the scalp, a unilateral response can be 
interpreted as a therapeutic success and a bilateral response as a spontaneous 
regrowth. Out of the 139 patients 107 had a unilateral response and no patients 
showed a bilateral response. 
In an unselected patient group of alopecia areata 12 out of 189 patients showed 
spontaneous regrowth (unpublished data P.H.M. van der Steen et al.). A three 
month period of the topical immunotherapy proved to be required for a first 
improvement and after more than 6 months treatment of a full remission may occur. 
Comparison of the effectiveness of dapsone with topical immunotherapy reveals that 
complete regrowth occurs in 22% and 50% of the patients respectively. It can be 
concluded that topical immunotherapy is far more effective compared to dapsone 
(Fisher's exact test: ρ < 0.006). 
Side effects are listed in Table V. In two out of 27 patients treated with 
dapsone (7%) the dose was reduced because of the increase in methaemoglobin (> 
5%). In 10 out of 27 patients the dose was lowered to 50 mg after a reduction of 
haemoglobin more than 1.6 g% in two weeks was seen. Analysis of liver function 
and kidney function revealed no significant abnormalities. Haematologic effects of 
dapsone like leucopenia and agranulocytosis were not reported. Three patients had 
symptoms of shortness of breath. 
Two patients had headache. One patient had sleep disorders, another patient had 
nausea. Fatigue was seen in three patients. Symptoms of peripheral neuropathy, like 
weakness, loss of sensation and paresthesias were not observed. Apart from the 
cutaneous side effects, sleep disturbances proved to be a significant problem during 
topical immunotherapy. 
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Table III. Hair growth during treatment 
Treatment 
Dapsone 
Type of AA 
Patchy 
ST/T/ST-U/U 
No of patients 
7 
20 
hair 
growth 
4 
10 
complete 
hair growth 
4(57 1%) 
2(10 0%) 
D Cpioi4 p a t c h y 44 34(77 3%) 
ST/T/ST-U/U 85 33 (38 8%) 
Diffuse/ophiasis 10 3 (30 0%) 
Spontaneous'5 '6 Patchy 20 12 (60%) 
Totalis 138 47 14 (10%) 
ST/T/ST-U/U = subtotal/total/subtotal universalis/universalis 
Table Г . Duration of treatment phases (months, mean ± S Ε M ) 
treatment duration until duration 
period first improve- until 
ment full 
remission 
Dapsone 
DCP l 0 
20 
43 
22 ± 06 
32 ± 02 
10 ± 0 7 
6 
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Table V. Side effects 
Side effects during 
treatment with dapsone 
nausea 
vomiting 
headache 
weakness 
fatigue 
dizziness 
shortness of breath 
sleep disorder 
anaemia 
methaemoglobinaemia 
cyanosis 
leucopema 
agranulocytosis 
hepatotoxicity 
nephrotoxicity 
peripheral neuropathy 
dapsone hypersensitivity 
syndrome 
1 (4%) 
-
2 (7%) 
-
3(11%) 
1 (4%) 
3(11%) 
1 (4%) 
10 (37%) 
2 (7%) 
1 (4%) 
-
-
-
-
-
-
Side effects during 
DCP 1 0 
mild contact eczema 
severe eczema/blister 
formation 
disseminated contact 
eczema 
urticaria 
swelling of the scalp 
edema of the eyelids/ 
face 
erythema multiforme-
like eruption 
swelling lymph nodes 
sleep disturbances 
headache 
139 (100%) 
81 (58 3 %) 
11(7 9%) 
7 (5 0%) 
1 (0 7%) 
5 (3 6%) 
2 (1 4%) 
139 (100%) 
48 (36 9%) 
3(2 3%) 
DISCUSSION 
From this study we may conclude that treatment of long-lasting alopecia areata with 
dapsone is less successful than topical immunotherapy (Fisher's exact test ρ < 
0 006) As the present investigation is not a placebo controlled study, the 
interpretation of the success of dapsone has to be interpreted in the light of the 
spontaneous recovery of alopecia areata15 1 6 The two patients, showing complete 
recovery of hair growth dunng treatment with dapsone, were treated with a low dose 
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of 50 mg a day and did not relapse following discontinuation of dapsone. Therefore, 
spontaneous recovery might well be the explanation of the favourable course in both 
patients. 
Table III shows the observations of Tosti et al. with respect to spontaneous 
regrowth in patients with the patchy type. Complete regrowth in this group 
occurred in 60% of the patients15. In the patients with the patchy type treated with 
dapsone (present study), 4 out of 7 patients (57%) received a cosmetically acceptable 
hair regrowth. 
The complete hair growth in patients with alopecia areata totalis/universalis without 
treatment has been reported by Muller and Winkelmann to be only 10 %16, which is 
equal to the effectiveness of dapsone. From these data, the conclusion can be drawn 
that the results of dapsone are comparable to spontaneous regrowth. 
The pathogenesis of alopecia areata is still unclear, however, there is 
considerable evidence pointing to an immunological mechanism. Numerous reports 
have documented the frequent coexistence of alopecia areata with other autoimmune 
disorders17 and its association with circulating auto-antibodies against various 
tissues'-8 " . In addition, certain more generalized disturbances in the immune status 
of the alopecia areata patients have been reported20 21. The immunohistological 
examination reveals peribulbar lymphocytic accumulations consisting predominantly 
of Τ helper cells 22 with a CD4/ CDB ratio of approximately 4:1". Expression of 
class I and class II antigens were found to be expressed by the hair matrix cells and 
submandibular epithelium, an event not occurring in normal skin. In alopecia areata 
there has been an increased number of Langerhans cells in the peribulbar and 
intrabulbar region24. During topical immunotherapy with DCP a modulation takes 
place, resulting in a change of the CD4/CD8 ratio from 4:1 to 1:1
й
. The Langerhans 
cells disappear in part or even completely and the expression of class I and class II 
major histocompatibility antigens disappear in part or even completely24. Dapsone 
has potent antiinflammatory actions. In dermatitis herpetiformis, pustular dermatoses 
and vasculitis dapsone has been demonstrated to be an effective treatment. Dapsone 
interferes with Chemotaxis of polymorphonuclear leucocytes and the respiratory burst 
of these cells26. Few data have been reported on the effect of dapsone on Τ cell 
functioning. It has been demonstrated by Wozel that phytohaemagglutinin induced Τ 
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cell transformation is inhibited by dapsone27 However Τ cell mediated diseases 
proved to show a poor therapeutical response to dapsone The negative results of 
dapsone in alopecia areata are m line with the supposition that alopecia areata is a Τ 
cell mediated disease 
In conclusion, the present study does not present any justification for the 
treatment of alopecia areata with dapsone as its efficacy remains doubtful and its 
side effects are substantial 
Acknowledgements 
The authors thank J В M Boezeman for statistical advice 
REFERENCES 
1 Mitchell AJ, Krull EA Alopecia areata pathogenesis and treatment J Am Acad 
Dermatol 1984,11 763-775 
2 Healy E, S Rogers S PUVA treatment for alopecia areata-does it work9 A 
retrospective review of 102 cases Br J Dermatol 1993,129 42-44 
3 Leyden JJ, Kligman AM Treatment of alopecia areata with steroid solution Arch 
Dermatol 1972,106 924 
4 Burton JL, Shuster S Large dose of glucocorticoid in the treatment of alopecia 
areata Acta Derm Venereol (Stockh) 1975,55 493^96 
5 de Prost Y, Teillac D, Paquez F et al Placebo-controlled trial of topical cyclosporin 
in severe alopecia areata Lancet 1986,2 803-804 
6 Gupta AK, Ellis CN, Cooper KD, et al Oral cyclosporin for the treatment of 
alopecia areata a clinical and immunohistochemical analysis J Am Acad Dermatol 
1990,22 242-250 
7 Price VH Topical minoxidil (3%) in extensive alopecia areata, including long-term 
efficacy J Am Acad Dermatol 1987,16 737-744 
8 Fiedler-Weiss VC, Rumsfiel J, Buys CM et al Evaluation of oral minoxidil in the 
treatment of alopecia areata Arch Dermatol 1987,123 1488-1490 
9 Galbraith GMP, Thiers BH, Jensen J et al A randomized double-blind study of 
inosiplex (Isopnnosine) therapy in patients with alopecia totalis J Am Acad 
Dermatol 1987,16 977-983 
10 van der Steen PHM, van Baar HMJ, Perret CM, et al Treatment of alopecia areata 
with diphenylcyclopropenone J Am Acad Dermatol 1991,24 253-258 
11 Hoting E, Boehm A Therapy of alopecia areata with diphencyprone Br J Dermatol 
1992,127 625-629 
12 Knauber J, Zaun Η Pathogeneseonentierte Therapieversuche bei Alopecia areata 
Vergleich von DCP und Dapson Akt Dermatol 1990,16 348-352 
13 Thiers BH Cutaneous appendage diseases alopecia areata In Provost TT, Farmer 
ER eds Current therapy in dermatology 1985 1986 Toronto В С Decker Ine 
1985 102-104 
14 van der Steen, van Baar HMJ, Happle R et al Prognostic factors m the treatment of 
Dapsone versus topical immunotherapy in alopecia areata 99 
alopecia areata with diphenylcyclopropenone J Am Acad Dermatol 1991,24 227-
230 
15 Tosti A, Padova MP, et al Therapies versus placebo in the treatment of patchy 
alopecia areata J Am Acad Dermatol 1986,15 209-210 
16 Muller SA, Winkelmann RK Alopecia areata Arch Dermatol 1963,88 290-297 
17 Friedmann PS Alopecia areata and auto-immunity Br J Dermatol 1981,105 153-
157 
18 Kern F, Hoffmann WH, Hambrick GW et al Alopecia areata Arch Dermatol 
1973,107 407-412 
19 Main RA, Robbie RB, Gray ES et al Smooth muscle antibodies and alopecia areata 
Br J Dermatol 1975,92 389-393 
20 Friedmann PS Decreased lymphocyte reactivity and auto-immunity m alopecia 
areata Br J Dermatol 1981,105 145-151 
21 GU SQ, Ros AM, Thyresson N et al Spontaneous cell-mediated cytotoxicity 
(SCMC) in patients with alopecia universalis Acta Derm Venereol (Stockh) 
1981,61 434-437 
22 Perret С, Brocker ЕВ, Wiesner-Menzel L et al In situ demonstration of Τ cells in 
alopecia areata Arch Dermatol Res 1982,273 155-158 
23 Perret С, Wiesner-Menzel L, Happle R Immunohistochemical analysis of T-cell 
subsets in the peribulbar and intrabulbar infiltrates of alopecia areata Acta Derm 
Venereol (Stockh) 1984,64 26-30 
24 Brocker EB, Echternacht-Happle K, Hamm Η et al Abnormal expression of class I 
and class II Major histocompatibility antigens in alopecia areata modulation by 
topical immunotherapy J Invest Dermatol 1987,88 564-568 
25 Happle R, Klein HM, Macher E Topical immunotherapy changes the composition 
of the peribulbar infiltrate in alopecia areata Arch Dermatol Res 1986,278 214-218 
26 Coleman MD Dapsone modes of action, toxicity and possible strategies for 
increasing patient tolerance Br J Dermatol 1993,129 507-513 
27 Wozel G Zum Wirkungsmechanismus von Dapsone bei chronisch entzündlichen 
Dermatosen Dermatol Mon sehr 1988,174(1) 1-9 
100 Chapter 7 
Chapter 8 
GENERAL DISCUSSION 

GENERAL DISCUSSION 
The studies presented and discussed in this thesis had the aim 
(i) to extend the understanding of normal hair growth in terms of epidermal 
proliferation, keratinization and expression of extracellular matrix molecules, 
by use of new immunohistochemical techniques; and to describe these "non-
immunological aspects" in alopecia areata 
(ii) to improve the therapeutic management of patients with alopecia areata. 
8.1 PATHOGENETIC ASPECTS 
Methodology 
The classical approach to study immunohistochemical aspects of hair follicles 
in health and disease is to process the biopsies for transversal sectioning. Although 
the orientation is easier on transverse sections, only a few follicles will appear in 
these sections which seriously limits a quantitative or semi-qualitative assessment. In 
particular in diseases such as alopecia areata with a decreased percentage of anagen 
hair follicles and a reduced size of follicles it is virtually impossible to investigate a 
sufficient number of hair follicles, by the classical approach of transverse sectioning. 
A second methodological drawback is that routine cryosectioning in cryo-microtomes 
does not allow temperatures below - 30°C. The coexistence of hair follicles and 
fatty tissue, however, requires such a low temperature, because of the differences in 
physicochemical properties between hair follicle and fatty tissue. A conduction 
system using liquid nitrogen, for temporary cooling down of the specimen, was 
developed. 
In chapter 2 the methodology of additional cooling of the tissue in the cryostat and 
the methodology of horizontal sectioning at various levels have been described. In 
chapter 3, 4 and 5 this methodology has been used to describe aspects of epidermal 
growth, keratinization and extracellular matrix at various levels of the hair follicle. 
For the assessment of the proliferative state in hair follicles, the antibody Ki-
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67 was used. Ki-67 is a monoclonal antibody that recognizes a human nuclear 
antigen associated with recruitment of cycling cells1. This Ki-67 antigen is expressed 
by cells participating in the cell cycle. In the assessment of the number of actively 
cycling cells, exclusively the nuclear staining pattern is of relevance. By using the 
monoclonal antibody Ki-67, a simple and rapid estimation of the growth fraction in 
hair follicles is possible. 
The immunohistochemical visualisation of extracellular matrix molecules 
(chapter 3) and keratins proved to be well reproducible (chapter 5). A limitation of 
this approach is that information is restricted to the presence of the proteins. In 
studies on the initiation of changes in cyclic processes such as the hair cycle not only 
the presence of the protein, but especially the regulation of the transcription of 
growth related factors is of relevance. In particular, the information on the phasing 
of processes can be blurred by proteins which may persist during long periods after 
the responsible initiating factor was operating. 
Functional morphology of normal hair follicles 
As mentioned in the introduction, the hair cycle comprises the anagen, 
catagen and telogen phase. The duration of the phase of the hair growth cycle may 
be influenced by environmental and systemic factors such as changes in photoperiod 
and circulating hormones2. It is well known that local factors are involved in 
regulating the cycle. Follicles transplanted from one body site to another remain in 
phase with the donor site for a prolonged period3, which suggests that control resides 
at the level of the hair follicle itself. There is evidence to assume that mesoderm 
derived components of the hair follicle comprising the dermal papilla and the 
connective tissue sheath are responsible for inducing and maintaining epithelial 
differentiation in the hair bulb matrix4. It is attractive to speculate on the identity of 
local manipulators of growth and differentiation of the hair follicles. The fibroblast, 
macrophages, Τ lymphocytes and mast cells all produce components of the network 
of cytokines which regulate growth and differentiation of the hair follicle. On the 
other hand extracellular matrix molecules interact with epithelial cell growth, 
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differentiation and migration by interacting with integrine. 
The anagen state of the hair cycle is characterized by a strong expression of 
extracellular matrix molecules around the hair follicle. The extracellular matrix 
diminishes during catagen and is minimal in the telogen follicle5. In chapter 3 it is 
shown that the human dermal papilla contains tenascin, fibronectin, laminin and 
heparan sulphate proteoglycan. Fibronectin, laminin and tenascin show a cyclic 
distribution pattern with a marked expression in the anagen phase with low 
expression in the catagen and telogen phase. Heparan sulphate proteoglycan proved 
to be independent from the stage of the hair cycle. As extracellular matrix molecules 
remain present throughout the hair growth cycles these molecules seem to have a 
structural role6. Expression of tenascin has been observed at subepidermal 
localisation in hyperproliferative conditions such as psoriasis, atopic dermatitis and 
the recovery following standardized injury7. It has been shown that tenascin 
expression is associated with epidermal hyperprol iferation8. Fibronectin and laminin 
are associated with migration and attachment of epidermal cells. The anagen phase 
of the hair cycle is the stage of epidermal proliferation and migration of epidermal 
cells and therefore the expression of the extracellular matrix molecules seems to be 
of biological significance. In chapter 4 it is shown that the recruitment of cycling 
epidermal cells (Ki-67 positive nuclei) is increased in the hair bulbs and in the outer 
root sheath of anagen hair. However, in the late anagen phase, catagen and telogen 
phase there are virtually no Ki-67 positive nuclei. In the interfollicular epidermis, an 
increased recruitment of cycling epidermal cells is associated with a pronounced 
increase of the number of keratin 16 cells9. In chapter 5 the expression of keratins 
proved to be independent from the hair cycle. The only cycle specific event was the 
observation that in telogen hair the central core of the hair was keratin 16 positive 
whereas in anagen hair the expression of this keratin was restricted to the hair bulb 
and the outer root sheath. 
Functional morphology of hair follicles in alopecia areata 
In alopecia areata the following changes were reported in chapter 3-5. 
(i) A dense infiltrate of T-lymphocytes is present in biopsies obtained 
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from involved skin, 
(ii) The expression of extracellular matrix molecules proved to be 
essentially normal in alopecia areata. However, at the sites of a dense 
inflammatory infiltrate the expression of tenascin was increased, 
(iii) When compared to normal scalp hair follicles, the follicles in alopecia 
areata were characterized by a marked decrease of the number of Ki-
67 positive nuclei, 
(iv) The decrease of the recruitment of cycling epidermal cells in the hair 
follicles in alopecia areata was not accompanied by a modulation of 
the cytokeratin expression. 
Based on the observations presented in chapters 3-5 we would like to put 
forward the hypothesis that the hair loss in alopecia areata is caused by a shift in the 
balance between anagen and telogen hair resulting in a relative preponderance of late 
anagen and telogen hair. The phenotype of late anagen and telogen hair is 
characterized by a decrease of the number of Ki-67 positive nuclei, with minor 
changes in the extracellular matrix and keratin expression pattern. This phenotype 
corresponds with the growth and differentiation characteristics in hair follicles of 
alopecia areata. 
The processes which might modulate the induction of anagen hair include 
circulating hormones. However, as alopecia areata is in part a local process, and as 
mesenchymal compounds have been shown to be of relevance with respect to 
induction and maintenance of the hair follicle, cellular components of the stroma 
might be of pathogenetic importance. Topical immunotherapy by repeated 
application of potent contact allergens (chapter 6) has been shown to induce a 
decrease of the CD4/CD8 ratio and to be very effective in the treatment of alopecia 
areata. In the light of the immunological observations it is attractive to hypothesize 
that a decrease of the CD4/CD8 ratio and the resulting shift of the local environment 
stimulate the recruitment of anagen hair follicles. Further studies on the coordination 
of the growth and differentiation of the hair follicle by surrounding factors are 
indicated to expand our knowledge on the pathogenesis of alopecia areata and to 
expand the horizon of potential treatment modalities of alopecia areata. 
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8.2 THERAPEUTICAL ASPECTS 
THE NATURAL HISTORY OF ALOPECIA AREATA 
The prognosis in various manifestations of alopecia areata 
The clinical course of alopecia areata is extremely variable, with some 
patients undergoing spontaneous remission and others progressing to total loss of 
scalp hair or complete loss of body and scalp hair. The more extensive the disease, 
the worse is the prognosis. The largest study on the natural history of alopecia areata 
is the investigation of Muller and Winkelmann, which included 736 patients10. In 
patients with alopecia areata totalis and universalis they reported that 44% of 
children and 34% of adults had subsequent significant periods of normal or near-
normal hair growth. Ten percent of the adults and 1% of the children showed 
permanent regrowth. Initial hair loss, mostly occurring in individual patches, tends 
to progress to alopecia areata totalis in only 6%n. Tosti showed regrowth in the 
patchy type group in 60% of the patients12. Our impression is that the spontaneous 
regrowth in the patchy type of alopecia areata is between 60 and 95 %. 
Prognostic factors and how to use these factors in general dermatological practice 
Because of its psychologically distressing effect, patients with severe alopecia 
areata make strong demands for treatment. It would be desirable to know prognostic 
factors that predict the response to treatment. Clinical features that provide a less 
favourable response to topical immunotherapy include a long duration of disease, a 
positive family history13 a personal history of atopy14, extensive alopecia areata15, 
early age of onset16 and presence of nail changes17. The present study (chapter 6.2) 
clearly demonstrates that the following prognostic factors are of significance: (1) 
type of alopecia areata as documented before treatment, (2) duration of the 
disease before therapy and (3) the presence of nail changes. The age of onset, 
sex, presence of atopic features and sleep disturbances caused by pruritus because of 
the contact eczema were of no relevance with respect to the prognosis. Topical 
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immunotherapy proved to have either an excellent or a satisfactory response in 
50 4% of the patients (chapter 6 1) 
For general dermatological practice it is clear that patchy type alopecia areata 
has a high rate of spontaneous regrowth, and waiting for spontaneous regrowth is by 
far the best approach In 50 4% of patients with an extensive alopecia areata 
significant regrowth will occur Several prognostic factors influence the chance of 
regrowth 
Which treatment to select7 
Among the therapeutic options listed m chapter 1, topical immunotherapy has 
been shown by various groups in controlled studies to be effective1819 Dapsone has 
challenged this unique position of topical immunotherapy In chapter 7, however 
dapsone-treated patients proved to grow hair approximately according to the natural 
course of the disease Therefore, dapsone is not an option in the treatment of 
alopecia areata 
It is a remarkable situation in medicine that topical immunotherapy, the only 
treatment which is effective in alopecia areata, persists to be experimental for many 
years 
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SUMMARY 
In chapter 1 (an overall introduction) general aspects of alopecia areata, namely 
clinical features, histopathological aspects, etiology, pathogenesis, and therapeutic 
modalities are reviewed. From a pathogenetic point of view, this thesis is focussed 
on the assessment of the distribution pattern of extracellular matrix proteins, 
epidermal proliferation and epidermal differentiation. After a discussion of the 
therapeutical aspects, the clinical efficacy, side effects and prognostic factors of 
topical immunotherapy with diphenylcyclopropenone are examined and compared 
with dapsone. 
In chapter 2 an improved method for horizontal cryosectioning of scalp biopsies is 
presented by a conduction system using liquid nitrogen. Hence, 
immunohistochemical methods in this thesis can be applied without restrictions. 
In chapter 3 tenascin (a recently discovered extracellular matrix protein) was 
demonstrated in perifollicular connective tissue of alopecia areata biopsies and 
compared with other extracellular matrix components like fibronectin, laminin and 
heparan sulphate proteoglycan. No gross differences between alopecia areata and 
normal scalp were noticed. The distribution of the four extracellular matrix 
components was accordingly to an established pattern. 
The presence of an increased expression of tenascin in the proximity of heavily 
infiltrated follicles in alopecia areata was striking. 
In chapter 4 the number of cycling cells in hair follicles of alopecia areata and 
normal scalp were determined with the proliferation-associated nuclear antigen by 
the monoclonal antibody Ki-67. Using an immunoperoxidase technique on 
cryosections, pronounced nuclear staining was limited below the critical line of 
Auber and the exterior part of the outer root sheath. 
In alopecia areata there is a reduced nuclear Ki-67 binding in the bulb of anagen hair 
follicles compared to normal scalp. 
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In chapter 5 the expression of different types of cytokeratins is described. The 
cytokeratins are expressed in defined anatomical parts of the hair follicle. Whilst 
keratin 16, which is modulated by conditions that affect the rate of keratinocyte 
proliferation, was found to be unchanged in the outer root of alopecia areata 
patients. There is a dissociation with the decrease in the expression of proliferation-
associated Ki-67 antigen, so that keratin 16 is marked for an increased degree of 
differentiation rather than a hyperproliferative state. 
In chapter 6 the efficacy of topical immunotherapy with diphenylcyclopropenone 
showed in 50.4% of the alopecia areata patients (majority with subtotal, total or 
universal type) an excellent or satisfactory result. 
Prognostic factors of importance are: type of alopecia areata as documented before 
treatment, duration of the disease before therapy, and the presence of nail changes. 
In chapter 7 topical immunotherapy and dapsone are compared in the treatment of 
alopecia areata. The rate of regrowth after dapsone treatment, is comparable to the 
rate of spontaneous regrowth, and this treatment can be, therefore, rejected as a 
therapy in the general practice. 
In chapter 8 the research aims and the results obtained are considered in a 
comprehensive perspective and some recommendations are given for further 
research. 
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SAMENVATTING 
In hoofdstuk 1 (de introductie) wordt een overzicht gegeven van algemene aspecten 
van alopecia areata, namelijk klinische en histopathologische kenmerken, aetiology, 
Pathogenese en therapeutische mogelijkheden. 
In dit proefschrift is vanuit een pathogenetische invalshoek de aandacht 
geconcentreerd op de beoordeling van het verdelingspatroon van extracellulaire 
matrix-eiwitten, epidermale proliferatie en epidermale differentiatie. 
Nadat de therapeutische aspecten zijn belicht, worden de klinische effectiviteit, 
bijwerkingen en prognostische factoren van de topische immunothérapie met 
diphenylcyclopropenon onderzocht en vervolgens vergeleken met dapson. 
In hoofdstuk 2 wordt een verbeterde methode gepresenteerd voor het horizontaal 
'cryo'- snijden van hoofdhuid-biopten door middel van een geleidingssysteem met 
vloeibare stikstof. 
In hoofdstuk 3 wordt tenascin - een recentelijk ontdekt extracellulair matrix-eiwit -
aangetoond in het perifollicular bindweefsel van 'alopecia areata'-biopten en 
vergeleken met andere extracellulaire matrix-eiwitten, namelijk met fibronectine, 
laminine en heparan sulfaat proteoglycaan. Er worden geen uitgesproken verschillen 
tussen alopecia areata en normale hoofdhuid waargenomen. De verdeling van de vier 
onderzochte extracellulaire matrix-componenten is volgens een specifiek patroon. 
Opvallend is de aanwezigheid van een toegenomen expressie van tenascin in de 
nabijheid van een dicht infiltraat rondom de haarfollikels. 
In hoofdstuk 4 wordt het aantal cyclische cellen in haarfollikels van alopecia areata 
en normale hoofdhuid bepaald met het proliferatie-geassocieerdc kern-antigeen. 
Hiervoor wordt het monoclonale antilichaam Ki-67 toegepast. Door gebruik te 
maken van een immunoperoxidase techniek op vries-coupes wordt een opvallende 
kernkleuring gezien. Deze kemkleuring beperkt zich tot onder de kritische lijn van 
Auber en het meest naar buiten gelegen deel van de buitenste wortelschede. 
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Bij alopecia areata wordt in vergelijking met de normale hoofdhuid, een 
gereduceerde 'Ki-67'-kernbinding in de bulbus van de anagene haarfollikels gezien. 
In hoofdstuk 5 wordt de expressie van verschillende cytokeratines beschreven. De 
cytokeratines komen tot expressie in anatomische gebieden van de haarfollikel 
volgens een bepaald patroon. Bovendien wordt cytokeratine 16, dat gereguleerd 
wordt door factoren, die van invloed zijn op de proliferatie van keratinocyten, 
onveranderd gevonden in de buitenste wortelschede. Er is een dissociatie tussen de 
vermindering van expressie van het proliferatie-geassocieerd Ki-67 antigeen en 
cytokeratine 16, zodat deze cytokeratine eerder kan worden beschouwd als maat 
voor de toegenomen differentiatie dan de mate van proliferatie. 
In hoofdstuk 6 laat de behandeling met de topische immunothérapie met 
diphenylcyclopropenon in 50.4% van de 'alopecia areata'-patiënten (meerderheid met 
subtotalis-, totalis- of universalis-type) een uitstekend tot bevredigend resultaat zien. 
Factoren van prognostische betekenis zijn: mate van haaraitval bij het begin van de 
therapie, ziekteduur voorafgaande aan behandeling en aanwezigheid van 
nagelveranderingen. 
In hoofdstuk 7 worden bij patiënten met alopecia areata de topische immunothérapie 
en dapson vergeleken. De mate van haargroei na behandeling met dapson is 
vergelijkbaar met de mate van spontaan herstel. Daarom kan deze therapie voor de 
algemene praktijk verworpen worden. 
In hoofdstuk 8 worden de vraagstellingen en de verkregen resultaten in een ruim 
perspectief in overweging genomen. Tevens worden aanbevelingen gegeven voor 
verder onderzoek. 
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STELLINGEN 
behorende bij het proefschrift 
ALOPECIA AREATA 
PATHOGENESIS AND THERAPY 
1 Dapson is niet geschikt voor de behandeling van alopecia areata Dit proefschrift 
2 'Cryo sectioning' met behulp van een geleidingssysteem waarin gebruik wordt 
gemaakt van vloeibare stikstof, is een zeer geschikte techniek voor het snijden van 
hoofdhuidbiopten van alopecia areata patiënten Dit proefschrift 
3 Topische ïmmuuntherapie is voor een uitgebreide alopecia areata de enige 
behandeling die tot een cosmetisch bevredigend resultaat kan leiden (P M Steijlen) 
4 In het penbulbaire infiltraat van 'alopecia areata'-haarfollikels is het extracellulaire 
matnx-eiwit tenascin opvallend aanwezig Dit proefschrift 
5 Rekening houdende met het vaak onleesbare handschrift van de meeste artsen, is het 
voor medische manuscriptcommissies maar goed dat de term 'manuscript' door 
promovendi niet al te letterlijk genomen wordt 
6 Kleine criminaliteit veroorzaakt grote ergernis 
7 Het in de volksmond, veelal door kale mannen, gebruikte gezegde 'daar waar 
verstand zit groeien geen haren', is een typisch staaltje van vrouwonvriendelijkheid 
8 Gezien het toegenomen aantal mannen met paardestaarten is het spreekwoord 'lange 
haren, kort verstand' niet alleen voor vrouwen een belediging 
9 Uit het feit dat laser-centra als paddestoelen uit de grond schieten, kan 
geconcludeerd worden dat het gezegde 'berouw komt na de zonde' op een groot 
aantal getatoeeerden van toepassing is 
10 Het woord 'almanak' in belastingalmanak moet gezien de omvang van de meeste 
belastingalmanakken, niet woordelijk genomen worden 
H.M.J. van Baar, 31 mei 1995 



